SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

OncoCyte Corp – ‘10-K’ for 12/31/16 – ‘EX-101.INS’

On:  Monday, 2/27/17, at 4:01pm ET   ·   For:  12/31/16   ·   Accession #:  1140361-17-9369   ·   File #:  1-37648

Previous ‘10-K’:  ‘10-K/A’ on 5/24/16 for 12/31/15   ·   Next:  ‘10-K’ on 4/2/18 for 12/31/17   ·   Latest:  ‘10-K’ on 4/16/24 for 12/31/23   ·   7 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/27/17  OncoCyte Corp                     10-K       12/31/16   51:7.2M                                   Broadridge Fin’l So… Inc

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Oncocyte Corporation 10-K 12-31-2016                HTML    774K 
 2: EX-4.3      Instrument Defining the Rights of Security Holders  HTML     84K 
 3: EX-4.4      Instrument Defining the Rights of Security Holders  HTML     84K 
 4: EX-4.5      Instrument Defining the Rights of Security Holders  HTML     75K 
 5: EX-10.26    Material Contract                                   HTML     79K 
 6: EX-10.29    Material Contract                                   HTML    218K 
 7: EX-23.1     Consent of Experts or Counsel                       HTML     15K 
 8: EX-31       Certification -- §302 - SOA'02                      HTML     26K 
 9: EX-32       Certification -- §906 - SOA'02                      HTML     17K 
16: R1          Document and Entity Information                     HTML     44K 
17: R2          Balance Sheets                                      HTML     89K 
18: R3          Balance Sheets (Parenthetical)                      HTML     34K 
19: R4          Statements of Operations                            HTML     42K 
20: R5          Statements of Comprehensive Loss                    HTML     30K 
21: R6          Statements of Stockholders' Equity (Deficit)        HTML     80K 
22: R7          Statements of Cash Flows                            HTML    100K 
23: R8          Organization, Description of the Business and       HTML     25K 
                Liquidity                                                        
24: R9          Summary of Significant Accounting Policies          HTML     75K 
25: R10         Selected Balance Sheet Components                   HTML     45K 
26: R11         Related Party Transactions                          HTML     26K 
27: R12         Related Party Convertible Promissory Note Payable   HTML     19K 
28: R13         Shareholders' Equity                                HTML     35K 
29: R14         Stock-based Compensation                            HTML     74K 
30: R15         Income Taxes                                        HTML     58K 
31: R16         Commitments and Contingencies                       HTML     28K 
32: R17         Subsequent Events                                   HTML     27K 
33: R18         Organization, Basis of Presentation and Liquidity   HTML     22K 
                (Policies)                                                       
34: R19         Summary of Significant Accounting Policies          HTML    124K 
                (Policies)                                                       
35: R20         Summary of Significant Accounting Policies          HTML     35K 
                (Tables)                                                         
36: R21         Selected Balance Sheet Components (Tables)          HTML     50K 
37: R22         Stock-based Compensation (Tables)                   HTML     69K 
38: R23         Income Taxes (Tables)                               HTML     54K 
39: R24         Organization, Description of the Business and       HTML     59K 
                Liquidity (Details)                                              
40: R25         Summary of Significant Accounting Policies          HTML    100K 
                (Details)                                                        
41: R26         Selected Balance Sheet Components (Details)         HTML     67K 
42: R27         Related Party Transactions (Details)                HTML     33K 
43: R28         Related Party Convertible Promissory Note Payable   HTML     52K 
                (Details)                                                        
44: R29         Shareholders' Equity (Details)                      HTML     86K 
45: R30         Stock-based Compensation (Details)                  HTML    119K 
46: R31         Income Taxes (Details)                              HTML    106K 
47: R32         Commitments and Contingencies (Details)             HTML     50K 
48: R33         Subsequent Events (Details)                         HTML     84K 
50: XML         IDEA XML File -- Filing Summary                      XML     77K 
49: EXCEL       IDEA Workbook of Financial Reports                  XLSX     65K 
10: EX-101.INS  XBRL Instance -- ocx-20161231                        XML   1.00M 
12: EX-101.CAL  XBRL Calculations -- ocx-20161231_cal                XML    125K 
13: EX-101.DEF  XBRL Definitions -- ocx-20161231_def                 XML    489K 
14: EX-101.LAB  XBRL Labels -- ocx-20161231_lab                      XML   1.37M 
15: EX-101.PRE  XBRL Presentations -- ocx-20161231_pre               XML    813K 
11: EX-101.SCH  XBRL Schema -- ocx-20161231                          XSD    115K 
51: ZIP         XBRL Zipped Folder -- 0001140361-17-009369-xbrl      Zip    146K

‘EX-101.INS’   —   XBRL Instance — ocx-20161231

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Generated by EDGARfilings PROfile 4.1.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved. -->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:ocx="http://oncocyte.com/20161231" xmlns="http://www.xbrl.org/2003/instance">
<link:schemaRef xlink:type="simple" xlink:href="ocx-20161231.xsd"/>
<xbrli:context id="c20160101to20161231">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160630">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-06-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-17 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20131231_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2013-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2013-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20131231">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2013-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20131231_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2013-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20141231">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2014-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2014-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20141231_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2014-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2014-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217_LegalEntityAxis_ParentCompanyMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-17 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170221_LegalEntityAxis_ParentCompanyMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-21 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217to20170217_LegalEntityAxis_ParentCompanyMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2017-02-17 </xbrli:startDate>
<xbrli:endDate> 2017-02-17 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160829">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-08-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160829_LegalEntityAxis_ParentCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-08-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231_LegalEntityAxis_ParentCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_LegalEntityAxis_ParentCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151118to20151118">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-11-18 </xbrli:startDate>
<xbrli:endDate> 2015-11-18 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis"> us-gaap:FiniteLivedIntangibleAssetsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> ocx:EquipmentAndFurnitureMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> ocx:EquipmentAndFurnitureMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:EquipmentMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:EquipmentMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_LegalEntityAxis_ParentCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_BalanceSheetLocationAxis_CurrentLiabilitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> ocx:CurrentLiabilitiesMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231_BalanceSheetLocationAxis_CurrentLiabilitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> ocx:CurrentLiabilitiesMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150502to20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> us-gaap:InvestorMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-05-02 </xbrli:startDate>
<xbrli:endDate> 2015-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151101to20151130_ExtinguishmentOfDebtAxis_ConvertibleDebtMember_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-11-01 </xbrli:startDate>
<xbrli:endDate> 2015-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150502to20150531_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-05-02 </xbrli:startDate>
<xbrli:endDate> 2015-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150531_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150531_ExtinguishmentOfDebtAxis_ConvertibleDebtMember_LegalEntityAxis_ParentCompanyMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150502to20150531_ExtinguishmentOfDebtAxis_LongTermDebtMember_LegalEntityAxis_ParentCompanyMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis"> us-gaap:LongTermDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-05-02 </xbrli:startDate>
<xbrli:endDate> 2015-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150502to20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> us-gaap:InvestorMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-05-02 </xbrli:startDate>
<xbrli:endDate> 2015-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150901to20150930_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-09-01 </xbrli:startDate>
<xbrli:endDate> 2015-09-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> us-gaap:InvestorMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ocx:StockPurchaseSubscriptionAgreementFirstMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160829to20160829">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-08-29 </xbrli:startDate>
<xbrli:endDate> 2016-08-29 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231_PlanNameAxis_StockOptionPlan2010Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> ocx:StockOptionPlan2010Member </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_PlanNameAxis_StockOptionPlan2010Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> ocx:StockOptionPlan2010Member </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20141231_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2014-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20151231_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2015-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2014-01-01 </xbrli:startDate>
<xbrli:endDate> 2014-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:StateAndLocalJurisdictionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_IncomeTaxAuthorityAxis_DomesticCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:DomesticCountryMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:DomesticCountryMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:StateAndLocalJurisdictionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:StateAndLocalJurisdictionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:DomesticCountryMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_TaxCreditCarryforwardAxis_ResearchMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis"> us-gaap:ResearchMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_RangeAxis_MaximumMember_TaxCreditCarryforwardAxis_ResearchMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis"> us-gaap:ResearchMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_RangeAxis_MinimumMember_TaxCreditCarryforwardAxis_ResearchMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis"> us-gaap:ResearchMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20150101to20151231_LegalEntityAxis_ParentCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2015-01-01 </xbrli:startDate>
<xbrli:endDate> 2015-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis"> ocx:MasterLeaseLineAgreementMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-04-07 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis"> ocx:MasterLeaseLineAgreementMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-04-07 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis"> ocx:MasterLeaseLineAgreementMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2016-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis"> ocx:MasterLeaseLineAgreementMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-04-07 </xbrli:startDate>
<xbrli:endDate> 2016-04-07 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160101to20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis"> ocx:MasterLeaseLineAgreementMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-01-01 </xbrli:startDate>
<xbrli:endDate> 2016-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis"> ocx:MasterLeaseLineAgreementMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2016-04-07 </xbrli:startDate>
<xbrli:endDate> 2016-04-07 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217to20170217_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2017-02-17 </xbrli:startDate>
<xbrli:endDate> 2017-02-17 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> ocx:SiliconValleyBankMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-21 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorsGroupTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis"> ocx:InvestorsGroupTwoMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-17 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-17 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorsGroupOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis"> ocx:InvestorsGroupOneMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-17 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217_LegalEntityAxis_ParentCompanyMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> us-gaap:ParentCompanyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-17 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170221to20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> ocx:SiliconValleyBankMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2017-02-21 </xbrli:startDate>
<xbrli:endDate> 2017-02-21 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis"> ocx:SiliconValleyBankMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2017-02-21 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="c20170217to20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_EmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001642380 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis"> ocx:EmployeesMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2017-02-17 </xbrli:startDate>
<xbrli:endDate> 2017-02-17 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="U001">
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="U002">
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="U003">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<xbrli:unit id="U004">
<xbrli:measure> xbrli:pure </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="U005">
<xbrli:measure> ocx:Segment </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="U006">
<xbrli:measure> ocx:Shareholder </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="U007">
<xbrli:measure> ocx:Vote </xbrli:measure>
</xbrli:unit>
<!-- Amendment Flag -->
<dei:AmendmentFlag contextRef="c20160101to20161231"> false </dei:AmendmentFlag>
<!-- Current Fiscal Year End Date -->
<dei:CurrentFiscalYearEndDate contextRef="c20160101to20161231"> --12-31 </dei:CurrentFiscalYearEndDate>
<!-- Document Period End Date -->
<dei:DocumentPeriodEndDate contextRef="c20160101to20161231"> 2016-12-31 </dei:DocumentPeriodEndDate>
<!-- Entity Well-known Seasoned Issuer -->
<dei:EntityWellKnownSeasonedIssuer contextRef="c20160101to20161231"> No </dei:EntityWellKnownSeasonedIssuer>
<!-- Entity Voluntary Filers -->
<dei:EntityVoluntaryFilers contextRef="c20160101to20161231"> No </dei:EntityVoluntaryFilers>
<!-- Entity Current Reporting Status -->
<dei:EntityCurrentReportingStatus contextRef="c20160101to20161231"> Yes </dei:EntityCurrentReportingStatus>
<!-- Entity Filer Category -->
<dei:EntityFilerCategory contextRef="c20160101to20161231"> Non-accelerated Filer </dei:EntityFilerCategory>
<!-- Entity Public Float -->
<dei:EntityPublicFloat contextRef="c20160630" unitRef="U001" decimals="-5"> 14700000 </dei:EntityPublicFloat>
<!-- Entity Registrant Name -->
<dei:EntityRegistrantName contextRef="c20160101to20161231"> OncoCyte Corp </dei:EntityRegistrantName>
<!-- Entity Central Index Key -->
<dei:EntityCentralIndexKey contextRef="c20160101to20161231"> 0001642380 </dei:EntityCentralIndexKey>
<!-- Entity Common Stock, Shares Outstanding -->
<dei:EntityCommonStockSharesOutstanding contextRef="c20170217" unitRef="U002" decimals="INF"> 29361616 </dei:EntityCommonStockSharesOutstanding>
<!-- Document Fiscal Year Focus -->
<dei:DocumentFiscalYearFocus contextRef="c20160101to20161231"> 2016 </dei:DocumentFiscalYearFocus>
<!-- Document Fiscal Period Focus -->
<dei:DocumentFiscalPeriodFocus contextRef="c20160101to20161231"> FY </dei:DocumentFiscalPeriodFocus>
<!-- Document Type -->
<dei:DocumentType contextRef="c20160101to20161231"> 10-K </dei:DocumentType>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Deficit [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Deficit [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> -304000 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Common Stock [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 0 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 75000 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -304000 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -21000 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Common Stock [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 0 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> -21000 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 75000 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Common Stock [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 0 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Deficit [Member] -->
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<!-- Accrued expenses and other current liabilities -->
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 1182000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<!-- Accrued expenses and other current liabilities -->
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 797000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<!-- Other accrued expenses -->
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 857000 </us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<!-- Other accrued expenses -->
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 248000 </us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<!-- Accounts Payable, Current -->
<us-gaap:AccountsPayableCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 285000 </us-gaap:AccountsPayableCurrent>
<!-- Accounts Payable, Current -->
<us-gaap:AccountsPayableCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 422000 </us-gaap:AccountsPayableCurrent>
<!-- Accrued Liabilities, Current -->
<us-gaap:AccruedLiabilitiesCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 325000 </us-gaap:AccruedLiabilitiesCurrent>
<!-- Accrued Liabilities, Current -->
<us-gaap:AccruedLiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 549000 </us-gaap:AccruedLiabilitiesCurrent>
<!-- Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment -->
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20161231" unitRef="U001" decimals="-3"> 319000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<!-- Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment -->
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20151231" unitRef="U001" decimals="-3"> 174000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<!-- Accumulated other comprehensive loss on available-for-sale securities -->
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20161231" unitRef="U001" decimals="-3"> -654000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<!-- Accumulated other comprehensive loss on available-for-sale securities -->
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20151231" unitRef="U001" decimals="-3"> -350000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<!-- Allocated Share-based Compensation Expense -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 922000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 1815000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 318000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Employee Stock Option [Member]-General and Administrative Expense [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3"> 141000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Research and Development [Member]-Employee Stock Option [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3"> 312000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Employee Stock Option [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3"> 1815000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Employee Stock Option [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3"> 922000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Employee Stock Option [Member]-Research and Development [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3"> 177000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Research and Development [Member]-Employee Stock Option [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3"> 456000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Employee Stock Option [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3"> 318000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Employee Stock Option [Member]-General and Administrative Expense [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3"> 610000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Allocated Share-based Compensation Expense-Employee Stock Option [Member]-General and Administrative Expense [Member] -->
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3"> 1359000 </us-gaap:AllocatedShareBasedCompensationExpense>
<!-- Amortization of intangible assets -->
<us-gaap:AmortizationOfIntangibleAssets contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 242000 </us-gaap:AmortizationOfIntangibleAssets>
<!-- Amortization of intangible assets -->
<us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 242000 </us-gaap:AmortizationOfIntangibleAssets>
<!-- Amortization of intangible assets -->
<us-gaap:AmortizationOfIntangibleAssets contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 242000 </us-gaap:AmortizationOfIntangibleAssets>
<!-- Antidilutive securities excluded from computation of earnings per share (in shares)-Warrant [Member] -->
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="-3"> 0 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<!-- Antidilutive securities excluded from computation of earnings per share (in shares)-Employee Stock Option [Member] -->
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 3017000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<!-- Antidilutive securities excluded from computation of earnings per share (in shares)-Warrant [Member] -->
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="-3"> 0 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<!-- Antidilutive securities excluded from computation of earnings per share (in shares)-Employee Stock Option [Member] -->
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20141231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 1361000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<!-- Antidilutive securities excluded from computation of earnings per share (in shares)-Warrant [Member] -->
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="-3"> 3246000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<!-- Antidilutive securities excluded from computation of earnings per share (in shares)-Employee Stock Option [Member] -->
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 2240000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<!-- Asset Impairment Charges -->
<us-gaap:AssetImpairmentCharges contextRef="c20160101to20161231" unitRef="U001" decimals="-6"> 0 </us-gaap:AssetImpairmentCharges>
<!-- Assets -->
<us-gaap:Assets contextRef="c20161231" unitRef="U001" decimals="-3"> 14447000 </us-gaap:Assets>
<!-- Assets -->
<us-gaap:Assets contextRef="c20151231" unitRef="U001" decimals="-3"> 12731000 </us-gaap:Assets>
<!-- Assets, Current -->
<us-gaap:AssetsCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 10925000 </us-gaap:AssetsCurrent>
<!-- Assets, Current -->
<us-gaap:AssetsCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 12696000 </us-gaap:AssetsCurrent>
<!-- Shares held as available-for-sale securities, at fair value -->
<us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 2237000 </us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
<!-- Shares held as available-for-sale securities, at fair value -->
<us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 2541000 </us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
<!-- Shares held as available-for-sale securities, at fair value-BioTime, Inc. [Member] -->
<us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="c20161231_LegalEntityAxis_ParentCompanyMember" unitRef="U001" decimals="-5"> 2200000 </us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
<!-- Basis of presentation -->
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Basis of presentation</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (“GAAP”). BioTime has consolidated the results of OncoCyte into BioTime’s consolidated results based on BioTime’s ability to control OncoCyte’s operating and financial decisions and policies through its majority ownership of OncoCyte common stock throughout the periods presented. BioTime owned 51.1% and 57.7% of the outstanding common stock of OncoCyte at December 31, 2016 and 2015, respectively.  As more fully discussed in Note 10, on February 17, 2017, BioTime’s percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of “control,” of OncoCyte as under GAAP and a result, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP as of February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime’s retained share ownership in OncoCyte which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte’s operations or management. Management evaluates the appropriateness of the percentage allocations on a quarterly basis and believes that this basis for allocation is reasonable.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.</div></div>
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<!-- Lease agreement value -->
<us-gaap:CapitalLeaseObligations contextRef="c20161231" unitRef="U001" decimals="-3"> 626000 </us-gaap:CapitalLeaseObligations>
<!-- Lease agreement value-Maximum [Member]-Master Lease Line Agreement [Member] -->
<us-gaap:CapitalLeaseObligations contextRef="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MaximumMember" unitRef="U001" decimals="-3"> 875000 </us-gaap:CapitalLeaseObligations>
<!-- Lease agreement value-Master Lease Line Agreement [Member] -->
<us-gaap:CapitalLeaseObligations contextRef="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3"> 458000 </us-gaap:CapitalLeaseObligations>
<!-- Lease agreement value-Master Lease Line Agreement [Member] -->
<us-gaap:CapitalLeaseObligations contextRef="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3"> 168000 </us-gaap:CapitalLeaseObligations>
<!-- Capital Lease Obligations, Current -->
<us-gaap:CapitalLeaseObligationsCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:CapitalLeaseObligationsCurrent>
<!-- Capital Lease Obligations, Current -->
<us-gaap:CapitalLeaseObligationsCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 202000 </us-gaap:CapitalLeaseObligationsCurrent>
<!-- Increment value of lease agreement-Minimum [Member]-Master Lease Line Agreement [Member] -->
<us-gaap:CapitalLeaseObligationsIncurred contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MinimumMember" unitRef="U001" decimals="-3"> 50000 </us-gaap:CapitalLeaseObligationsIncurred>
<!-- Capital-Subsequent Event [Member]-BioTime, Inc. [Member]-Maximum [Member] -->
<us-gaap:Capital contextRef="c20170221_LegalEntityAxis_ParentCompanyMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5"> 2000000 </us-gaap:Capital>
<!-- Fair value of equipment at inception-Master Lease Line Agreement [Member] -->
<us-gaap:CapitalLeasedAssetsNoncurrentFairValueDisclosure contextRef="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3"> 626000 </us-gaap:CapitalLeasedAssetsNoncurrentFairValueDisclosure>
<!-- Monthly payment under capital lease-Master Lease Line Agreement [Member] -->
<us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="0"> 5342 </us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
<!-- Monthly payment under capital lease-Master Lease Line Agreement [Member] -->
<us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="0"> 14442 </us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
<!-- Capital lease liability -->
<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 310000 </us-gaap:CapitalLeaseObligationsNoncurrent>
<!-- Capital lease liability -->
<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:CapitalLeaseObligationsNoncurrent>
<!-- Cash -->
<us-gaap:Cash contextRef="c20151231" unitRef="U001" decimals="-5"> 8000000 </us-gaap:Cash>
<!-- Cash -->
<us-gaap:Cash contextRef="c20161231" unitRef="U001" decimals="-5"> 10200000 </us-gaap:Cash>
<!-- Cash and cash equivalents -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20161231" unitRef="U001" decimals="-3"> 10174000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<!-- Cash and cash equivalents -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20151231" unitRef="U001" decimals="-3"> 7996000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<!-- Cash and cash equivalents -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20131231" unitRef="U001" decimals="-3"> 101000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<!-- Cash and cash equivalents -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20141231" unitRef="U001" decimals="-3"> 257000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<!-- Cash and Cash Equivalents, Policy [Policy Text Block] -->
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Cash and cash equivalents</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2016 and 2015, OncoCyte's cash balances totaled $10.2 million and $8.0 million, respectively, and consist of bank account deposits and $9.4 million held in money market funds at December 31, 2016.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.</div></div>
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<!-- Cash and Cash Equivalents, Period Increase (Decrease) -->
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 156000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<!-- Cash and Cash Equivalents, Period Increase (Decrease) -->
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 7739000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<!-- Cash and Cash Equivalents, Period Increase (Decrease) -->
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 2178000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<!-- Class of Warrant or Right, Number of Securities Called by Each Warrant or Right-BioTime, Inc. [Member] -->
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c20160829_LegalEntityAxis_ParentCompanyMember" unitRef="U002" decimals="INF"> 1 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<!-- Class of Warrant or Right, Number of Securities Called by Each Warrant or Right -->
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c20160829" unitRef="U002" decimals="INF"> 1 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<!-- Class of Warrant or Right, Number of Securities Called by Warrants or Rights-Subsequent Event [Member]-Investors Group One [Member] -->
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorsGroupOneMember" unitRef="U002" decimals="INF"> 200000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<!-- Class of Warrant or Right, Number of Securities Called by Warrants or Rights-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="INF"> 8247 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<!-- Class of Warrant or Right, Number of Securities Called by Warrants or Rights-Subsequent Event [Member]-Investors Group Two [Member] -->
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorsGroupTwoMember" unitRef="U002" decimals="INF"> 212500 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<!-- Class of Warrant or Right, Outstanding-Subsequent Event [Member] -->
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20170217_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="INF"> 3033653 </us-gaap:ClassOfWarrantOrRightOutstanding>
<!-- Class of Warrant or Right, Exercise Price of Warrants or Rights-Subsequent Event [Member]-BioTime, Inc. [Member] -->
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170217_LegalEntityAxis_ParentCompanyMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2"> 3.25 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<!-- Class of Warrant or Right, Exercise Price of Warrants or Rights -->
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20161231" unitRef="U003" decimals="INF"> 3.25 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<!-- Class of Warrant or Right, Exercise Price of Warrants or Rights-Silicon Valley Bank [Member]-Subsequent Event [Member] -->
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2"> 4.85 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<!-- Class of Warrant or Right, Exercise Price of Warrants or Rights-Subsequent Event [Member]-Investors Group Two [Member] -->
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorsGroupTwoMember" unitRef="U003" decimals="2"> 3.25 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<!-- Class of Warrant or Right, Exercise Price of Warrants or Rights-Subsequent Event [Member] -->
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170217_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2"> 3.25 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<!-- Class of Warrant or Right, Exercise Price of Warrants or Rights-Investors Group One [Member]-Subsequent Event [Member] -->
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorsGroupOneMember" unitRef="U003" decimals="2"> 5.50 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<!-- Commitments and Contingencies Disclosure [Text Block] -->
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">9. Commitments and Contingencies</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte had no commitments other than those under the Shared Facilities and Services Agreement described in Note 4. The minimum fixed payments due under the Shared Facilities Agreement are approximately $15,000 per month.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Tax Filings</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes OncoCyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the financial statements.</div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Master Lease Line Agreement</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On April 7, 2016, OncoCyte entered into a Master Lease Line Agreement (the “Lease Agreement”) with an unrelated financing company for the purchase and financing of certain equipment. OncoCyte may use up to $875,000 for purchases of equipment financed by the Lease Agreement between March 29, 2016 through March 28, 2017, the expiration date of the availability of funds under the Lease Agreement. Each lease schedule OncoCyte enters into under the Lease Agreement must be in minimum increments of $50,000 each with a 36-month lease term, collateralized by the equipment financed under the lease schedule. Each lease schedule requires a deposit for the first and last payment under that schedule. Monthly payments will be determined using a lease factor approximating an interest rate of 10% per annum. At the end of each lease schedule under the Lease Agreement, assuming no default has occurred, OncoCyte may either return the equipment financed under the schedule for a restocking fee of 7.5% of the original cost of the equipment or purchase the equipment from the financing company at a fair value not less than 12.5% of the original cost of the equipment.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On April 7, 2016, OncoCyte entered into a lease schedule under the Lease Agreement for certain equipment costing approximately $458,000, requiring payments of $14,442 per month over 36 months. In December 2016, OncoCyte entered into a lease schedule under the Lease Agreement for certain equipment costing approximately $168,000, requiring payments of $5,342 per month over 36 months.  OncoCyte has accounted for these leases as a capital lease in accordance with ASC 840,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Leases</font>, due to the net present value of the payments under the lease approximating the fair value of the equipment at inception of the lease, or approximately $626,000. The payments under the lease schedules will be amortized to capital lease obligations and interest expense using the interest method at an imputed rate of approximately 10% per annum. As of December 31, 2016, there was approximately $249,000 available under the Lease Agreement for future purchases and financing of equipment.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Litigation – General</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When OncoCyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, OncoCyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, OncoCyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. OncoCyte is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Employment Contracts</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has entered into employment contracts with certain executive officers. Under the provisions of the contracts, OncoCyte may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations. At December 31, 2016, total potential severance obligations in connection with the termination of employment contracts approximated $420,000 for termination without cause and $624,000 for termination due to a change in control.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Indemnification</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In the normal course of business, OncoCyte may provide indemnification of varying scope under OncoCyte’s agreements with other companies or consultants, typically OncoCyte’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, OncoCyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of OncoCyte’s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to OncoCyte’s diagnostic tests. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments OncoCyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, OncoCyte has not been subject to any claims or demands for indemnification. OncoCyte also maintains various liability insurance policies that limit OncoCyte’s financial exposure. As a result, OncoCyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, OncoCyte has not recorded any liabilities for these agreements as of December 31, 2016 and 2015.</div></div>
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<!-- Commitments and contingencies (see Note 9) -->
<us-gaap:CommitmentsAndContingencies contextRef="c20151231" unitRef="U001" xsi:nil="true"/>
<!-- Commitments and contingencies (see Note 9) -->
<us-gaap:CommitmentsAndContingencies contextRef="c20161231" unitRef="U001" xsi:nil="true"/>
<!-- Common stock, shares issued (in shares) -->
<us-gaap:CommonStockSharesIssued contextRef="c20161231" unitRef="U002" decimals="-3"> 28737000 </us-gaap:CommonStockSharesIssued>
<!-- Common stock, shares issued (in shares) -->
<us-gaap:CommonStockSharesIssued contextRef="c20151231" unitRef="U002" decimals="-3"> 25391000 </us-gaap:CommonStockSharesIssued>
<!-- Common stock, shares issued (in shares)-BioTime, Inc. [Member] -->
<us-gaap:CommonStockSharesIssued contextRef="c20151231_LegalEntityAxis_ParentCompanyMember" unitRef="U002" decimals="INF"> 259712 </us-gaap:CommonStockSharesIssued>
<!-- Common shares, par value (in dollars per share) -->
<us-gaap:CommonStockNoParValue contextRef="c20161231" unitRef="U003" decimals="INF"> 0 </us-gaap:CommonStockNoParValue>
<!-- Common shares, par value (in dollars per share) -->
<us-gaap:CommonStockNoParValue contextRef="c20151231" unitRef="U003" decimals="INF"> 0 </us-gaap:CommonStockNoParValue>
<!-- Common stock, shares authorized (in shares) -->
<us-gaap:CommonStockSharesAuthorized contextRef="c20151231" unitRef="U002" decimals="-3"> 50000000 </us-gaap:CommonStockSharesAuthorized>
<!-- Common stock, shares authorized (in shares) -->
<us-gaap:CommonStockSharesAuthorized contextRef="c20161231" unitRef="U002" decimals="-3"> 50000000 </us-gaap:CommonStockSharesAuthorized>
<!-- Common stock, no par value, 50,000 shares authorized; 28,737 and 25,391 shares issued and outstanding at December 31, 2016 and 2015, respectively -->
<us-gaap:CommonStockValue contextRef="c20151231" unitRef="U001" decimals="-3"> 34901000 </us-gaap:CommonStockValue>
<!-- Common stock, no par value, 50,000 shares authorized; 28,737 and 25,391 shares issued and outstanding at December 31, 2016 and 2015, respectively -->
<us-gaap:CommonStockValue contextRef="c20161231" unitRef="U001" decimals="-3"> 45818000 </us-gaap:CommonStockValue>
<!-- Common shares, shares outstanding (in shares) -->
<us-gaap:CommonStockSharesOutstanding contextRef="c20151231" unitRef="U002" decimals="-3"> 25391000 </us-gaap:CommonStockSharesOutstanding>
<!-- Common shares, shares outstanding (in shares) -->
<us-gaap:CommonStockSharesOutstanding contextRef="c20161231" unitRef="U002" decimals="-3"> 28737000 </us-gaap:CommonStockSharesOutstanding>
<!-- Common shares, shares outstanding (in shares)-Common Stock [Member] -->
<us-gaap:CommonStockSharesOutstanding contextRef="c20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 18200000 </us-gaap:CommonStockSharesOutstanding>
<!-- Common shares, shares outstanding (in shares)-Common Stock [Member] -->
<us-gaap:CommonStockSharesOutstanding contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 18200000 </us-gaap:CommonStockSharesOutstanding>
<!-- Common shares, shares outstanding (in shares)-Common Stock [Member] -->
<us-gaap:CommonStockSharesOutstanding contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 28737000 </us-gaap:CommonStockSharesOutstanding>
<!-- Common shares, shares outstanding (in shares)-Common Stock [Member] -->
<us-gaap:CommonStockSharesOutstanding contextRef="c20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 25391000 </us-gaap:CommonStockSharesOutstanding>
<!-- Comprehensive Income (Loss), Net of Tax, Attributable to Parent -->
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -11472000 </us-gaap:ComprehensiveIncomeNetOfTax>
<!-- Comprehensive Income (Loss), Net of Tax, Attributable to Parent -->
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -4438000 </us-gaap:ComprehensiveIncomeNetOfTax>
<!-- Comprehensive Income (Loss), Net of Tax, Attributable to Parent -->
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> -8263000 </us-gaap:ComprehensiveIncomeNetOfTax>
<!-- Equipment purchased under capital leases -->
<us-gaap:ContributionOfProperty contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:ContributionOfProperty>
<!-- Equipment purchased under capital leases -->
<us-gaap:ContributionOfProperty contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 626000 </us-gaap:ContributionOfProperty>
<!-- Equipment purchased under capital leases -->
<us-gaap:ContributionOfProperty contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:ContributionOfProperty>
<!-- Common stock shares converted (in shares)-BioTime, Inc. [Member]-Common Stock [Member]-Stock Purchase Subscription Agreement, First [Member] -->
<us-gaap:ConversionOfStockSharesConverted1 contextRef="c20150101to20151231_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U002" decimals="INF"> 20 </us-gaap:ConversionOfStockSharesConverted1>
<!-- Convertible Debt, Fair Value Disclosures-BioTime, Inc. [Member]-Stock Purchase Subscription Agreement, First [Member]-Convertible Debt [Member] -->
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c20150531_ExtinguishmentOfDebtAxis_ConvertibleDebtMember_LegalEntityAxis_ParentCompanyMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="-5"> 3300000 </us-gaap:ConvertibleDebtFairValueDisclosures>
<!-- Convertible Debt-BioTime, Inc. [Member]-Convertible Debt [Member]-Stock Purchase Subscription Agreement, First [Member] -->
<us-gaap:ConvertibleDebt contextRef="c20150531_ExtinguishmentOfDebtAxis_ConvertibleDebtMember_LegalEntityAxis_ParentCompanyMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="-5"> 3300000 </us-gaap:ConvertibleDebt>
<!-- Debt Conversion, Converted Instrument, Amount-Common Stock [Member] -->
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 3300000 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<!-- Debt Conversion, Converted Instrument, Amount-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<!-- Debt Conversion, Converted Instrument, Amount -->
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 3300000 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<!-- Debt Conversion, Converted Instrument, Amount-Accumulated Deficit [Member] -->
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<!-- Debt Conversion, Converted Instrument, Amount -->
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<!-- Debt Conversion, Converted Instrument, Amount -->
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<!-- Debt Conversion, Converted Instrument, Amount-BioTime, Inc. [Member]-Common Stock [Member]-Stock Purchase Subscription Agreement, First [Member] -->
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150502to20150531_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="-5"> 3300000 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<!-- Debt Conversion, Converted Instrument, Shares Issued-Common Stock [Member] -->
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 1500000 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<!-- Debt Conversion, Converted Instrument, Shares Issued-Stock Purchase Subscription Agreement, First [Member]-Convertible Debt [Member]-BioTime, Inc. [Member]-Common Stock [Member] -->
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c20151101to20151130_ExtinguishmentOfDebtAxis_ConvertibleDebtMember_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U002" decimals="INF"> 1508095 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<!-- Debt Conversion, Converted Instrument, Shares Issued-BioTime, Inc. [Member]-Common Stock [Member]-Stock Purchase Subscription Agreement, First [Member] -->
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c20150502to20150531_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U002" decimals="INF"> 1500000 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<!-- Basis spread variable rate-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20170221to20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="4"> 0.0075 </us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
<!-- Base rate-Silicon Valley Bank [Member]-Subsequent Event [Member] -->
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="4"> 0.0425 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<!-- Deferred Tax Liabilities, Investments -->
<us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c20161231" unitRef="U001" decimals="-3"> 761000 </us-gaap:DeferredTaxLiabilitiesInvestments>
<!-- Deferred Tax Liabilities, Investments -->
<us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c20151231" unitRef="U001" decimals="-3"> 864000 </us-gaap:DeferredTaxLiabilitiesInvestments>
<!-- Deferred Tax Liabilities, Gross -->
<us-gaap:DeferredIncomeTaxLiabilities contextRef="c20151231" unitRef="U001" decimals="-3"> 864000 </us-gaap:DeferredIncomeTaxLiabilities>
<!-- Deferred Tax Liabilities, Gross -->
<us-gaap:DeferredIncomeTaxLiabilities contextRef="c20161231" unitRef="U001" decimals="-3"> 761000 </us-gaap:DeferredIncomeTaxLiabilities>
<!-- Deferred Tax Assets, Net of Valuation Allowance -->
<us-gaap:DeferredTaxAssetsNet contextRef="c20161231" unitRef="U001" decimals="-3"> 761000 </us-gaap:DeferredTaxAssetsNet>
<!-- Deferred Tax Assets, Net of Valuation Allowance -->
<us-gaap:DeferredTaxAssetsNet contextRef="c20151231" unitRef="U001" decimals="-3"> 864000 </us-gaap:DeferredTaxAssetsNet>
<!-- Net operating loss carryforwards -->
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20151231" unitRef="U001" decimals="-3"> 8139000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<!-- Net operating loss carryforwards -->
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20161231" unitRef="U001" decimals="-3"> 11730000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<!-- Deferred Tax Assets, Net -->
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:DeferredTaxAssetsLiabilitiesNet>
<!-- Deferred Tax Assets, Net -->
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:DeferredTaxAssetsLiabilitiesNet>
<!-- Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost -->
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20151231" unitRef="U001" decimals="-3"> 98000 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<!-- Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost -->
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20161231" unitRef="U001" decimals="-3"> 1041000 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<!-- Research and development credit carryforwards -->
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c20161231" unitRef="U001" decimals="-3"> 1765000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<!-- Research and development credit carryforwards -->
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c20151231" unitRef="U001" decimals="-3"> 1362000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<!-- Deferred Tax Assets, Valuation Allowance -->
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20151231" unitRef="U001" decimals="-3"> 8871000 </us-gaap:DeferredTaxAssetsValuationAllowance>
<!-- Deferred Tax Assets, Valuation Allowance -->
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20161231" unitRef="U001" decimals="-3"> 13954000 </us-gaap:DeferredTaxAssetsValuationAllowance>
<!-- Deposits -->
<us-gaap:DepositsAssetsNoncurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 75000 </us-gaap:DepositsAssetsNoncurrent>
<!-- Deposits -->
<us-gaap:DepositsAssetsNoncurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:DepositsAssetsNoncurrent>
<!-- Depreciation expense -->
<us-gaap:Depreciation contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 39000 </us-gaap:Depreciation>
<!-- Depreciation expense -->
<us-gaap:Depreciation contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 145000 </us-gaap:Depreciation>
<!-- Depreciation expense -->
<us-gaap:Depreciation contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 41000 </us-gaap:Depreciation>
<!-- Disclosure of Compensation Related Costs, Share-based Payments [Text Block] -->
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">7. Stock-based Compensation</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Stock Option Plan</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has adopted a 2010 Stock Option Plan (the “Plan”) under which OncoCyte initially authorized 2,000,000 shares of common stock for the grant of stock options or the sale of restricted stock.  The Plan was amended to increase the authorized shares available for grant by 2,000,000 in 2015. The Plan also permits OncoCyte to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">No options may be granted under the Plan more than ten years after the date upon which the Plan was adopted by the Board of Directors, and no options granted under the Plan may be exercised after the expiration of ten years from the date of grant. Under the Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of common stock at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. Generally, OncoCyte stock options have service related vesting conditions based on the continued performance of services for OncoCyte. The Plan also permits OncoCyte to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. OncoCyte may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. To date, only stock options have been issued under the Plan.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As discussed in Note 4, in connection with the services performed by employees of BioTime, or employees of other BioTime subsidiaries, OncoCyte grants stock options to those employees performing services for OncoCyte and records stock-based compensation expense in the accompanying statements of operations for these services performed in the periods presented.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Stock Options</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Options granted under the Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), or non-qualified stock options. Incentive stock options may be granted only to OncoCyte employees and employees of its subsidiaries, if any. The exercise price of stock options granted under the Plan must be equal to the fair market value of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of OncoCyte common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The options’ exercise price may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board of Directors or Compensation Committee may approve.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Incentive stock options granted under the Plan are nontransferable except by will or the laws of descent and distribution and may be exercised only during employment or within three months after termination of such employment, subject to certain exceptions in the event of the death or disability of the optionee.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Options other than incentive stock options under the Code are also nontransferable except by will or the laws of descent and distribution, except to the extent that the Board of Directors or Committee permits the optionee to transfer an option to a family member, a trust for family members, or other persons approved by the Board of Directors or Committee in its discretion.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter as approved by the Board of Directors or Committee, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The number of shares of common stock covered by the Plan, and the number of shares of common stock and the exercise price per share of each outstanding option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding shares of common stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other increase or decrease in the number of issued and outstanding shares of common stock effected without receipt of consideration by OncoCyte.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Options Granted</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2016, 880,417 shares were available for future grants under the Plan.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 64%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">for</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Grant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Options </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Outstanding</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Price</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total at January 1, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">639</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,361</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.52</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Increase in option pool</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,000</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options granted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,448</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,448</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.21</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options exercised</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options forfeited or cancelled</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">566</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(566</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.59</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total at December 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,757</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.03</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options granted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(962</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">962</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.58</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options exercised</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(100</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.19</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options forfeited, cancelled or expired</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">85</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(85</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.00</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total at December 31, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">880</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.52</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Exercisable at December 31, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 6%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,591</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.83</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">At December 31, 2016 and 2015, OncoCyte had approximately $2.7 million and $1.5 million, respectively, of total unrecognized compensation expense, net of estimated forfeitures, related to the Plan that will be recognized over a weighted-average period of approximately 2.4 and 3.0 years, respectively.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2016, 2015 and 2014 (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Research and development</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">312</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">456</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">177</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">General and administrative</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">610</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.07%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,359</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.07%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">141</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.07%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total stock-based compensation expense</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">922</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,815</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">318</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The assumptions that were used to calculate the grant date fair value of OncoCyte’s employee and non-employee stock option grants for the years ended December 31, 2016, 2015 and 2014 were as follows.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014<font style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Expected life (in years)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6.21</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6.83</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rates</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.46</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.87</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">64.64</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">74.15</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr></table><div style="text-align: justify;"> </div><div style="text-align: justify; margin-left: 45pt;"><hr align="left" noshade="noshade" style="border-top: medium none; height: 2px; border-right: medium none; border-bottom: medium none; color: #000000; text-align: left; margin-left: 0px; border-left: medium none; width: 90%; background-color: #000000; margin-right: auto;" /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; width: 18pt; align: right;">(1)</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';">No stock options were granted in 2014.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Stock-based compensation expense is recognized based on awards that are ultimately expected to vest, and as a result, the amount has been reduced by estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on OncoCyte’s historical experience and future expectations.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If OncoCyte had made different assumptions, its stock-based compensation expense, and net loss for years ended December 31, 2016, 2015 and 2014, may have been significantly different.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">There was no net income tax benefit recognized in the statements of operations for stock-based compensation expense for non-qualified stock options, as OncoCyte fully offsets net deferred tax assets with a valuation allowance (see Note 8). In addition, OncoCyte does not recognize deferred income taxes for incentive stock option compensation expense, and records a tax deduction only when a disqualified disposition has occurred.</div></div>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<!-- OncoCyte common stock received as a dividend in kind from BioTime-Accumulated Deficit [Member] -->
<us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:DividendsCommonStockPaidinkind>
<!-- OncoCyte common stock received as a dividend in kind from BioTime-Common Stock [Member] -->
<us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 0 </us-gaap:DividendsCommonStockPaidinkind>
<!-- OncoCyte common stock received as a dividend in kind from BioTime-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:DividendsCommonStockPaidinkind>
<!-- OncoCyte common stock received as a dividend in kind from BioTime -->
<us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:DividendsCommonStockPaidinkind>
<!-- Amount due to parent, BioTime -->
<us-gaap:DueToRelatedPartiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 2703000 </us-gaap:DueToRelatedPartiesCurrent>
<!-- Amount due to parent, BioTime -->
<us-gaap:DueToRelatedPartiesCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 807000 </us-gaap:DueToRelatedPartiesCurrent>
<!-- Amount due to affiliates -->
<us-gaap:DueToAffiliateCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 40000 </us-gaap:DueToAffiliateCurrent>
<!-- Amount due to affiliates -->
<us-gaap:DueToAffiliateCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 151000 </us-gaap:DueToAffiliateCurrent>
<!-- Basic and diluted net loss per share (in dollars per share) -->
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20140101to20141231" unitRef="U003" decimals="2"> -0.27 </us-gaap:EarningsPerShareBasicAndDiluted>
<!-- Basic and diluted net loss per share (in dollars per share) -->
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20150101to20151231" unitRef="U003" decimals="2"> -0.42 </us-gaap:EarningsPerShareBasicAndDiluted>
<!-- Basic and diluted net loss per share (in dollars per share) -->
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20160101to20161231" unitRef="U003" decimals="2"> -0.42 </us-gaap:EarningsPerShareBasicAndDiluted>
<!-- Earnings Per Share, Policy [Policy Text Block] -->
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Net loss per common share</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The computations of basic and diluted net loss per common share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share amounts):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net loss</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(11,168</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,735</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4,986</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Weighted average common shares outstanding – basic and diluted</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,529</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,009</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">18,200</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net loss per common share – basic and diluted</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.27</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr></table><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2016, 2015 and 2014 because including them would have been antidilutive (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Stock options under Stock Option Plan</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,361</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,246</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div>
</us-gaap:EarningsPerSharePolicyTextBlock>
<!-- Computed tax benefit at federal statutory rate -->
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20140101to20141231" unitRef="U004" decimals="2"> 0.34 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<!-- Computed tax benefit at federal statutory rate -->
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20160101to20161231" unitRef="U004" decimals="2"> 0.34 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<!-- Computed tax benefit at federal statutory rate -->
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20150101to20151231" unitRef="U004" decimals="2"> 0.34 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<!-- State tax benefit -->
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c20150101to20151231" unitRef="U004" decimals="2"> 0.15 </us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<!-- State tax benefit -->
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c20160101to20161231" unitRef="U004" decimals="2"> 0.02 </us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<!-- State tax benefit -->
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c20140101to20141231" unitRef="U004" decimals="0"> 0 </us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<!-- Research and development credits -->
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c20150101to20151231" unitRef="U004" decimals="2"> 0.02 </us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
<!-- Research and development credits -->
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c20140101to20141231" unitRef="U004" decimals="2"> 0.02 </us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
<!-- Research and development credits -->
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c20160101to20161231" unitRef="U004" decimals="2"> 0.02 </us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
<!-- Other -->
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c20150101to20151231" unitRef="U004" decimals="2"> 0.03 </us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
<!-- Other -->
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c20160101to20161231" unitRef="U004" decimals="2"> 0.07 </us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
<!-- Other -->
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c20140101to20141231" unitRef="U004" decimals="0"> 0 </us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
<!-- Change in valuation allowance -->
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20150101to20151231" unitRef="U004" decimals="2"> -0.45 </us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<!-- Change in valuation allowance -->
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20140101to20141231" unitRef="U004" decimals="2"> -0.34 </us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<!-- Change in valuation allowance -->
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20160101to20161231" unitRef="U004" decimals="2"> -0.44 </us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<!-- Effective Income Tax Rate Reconciliation, Percent -->
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20160101to20161231" unitRef="U004" decimals="0"> 0 </us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<!-- Effective Income Tax Rate Reconciliation, Percent -->
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20140101to20141231" unitRef="U004" decimals="0"> 0 </us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<!-- Effective Income Tax Rate Reconciliation, Percent -->
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20150101to20151231" unitRef="U004" decimals="0"> 0 </us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<!-- Weighted average recognition period-Employee Stock Option [Member] -->
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember"> P2Y4M24D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<!-- Weighted average recognition period-Employee Stock Option [Member] -->
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember"> P3Y </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<!-- Total unrecognized compensation costs-Employee Stock Option [Member] -->
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5"> 2700000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<!-- Total unrecognized compensation costs-Employee Stock Option [Member] -->
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5"> 1500000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<!-- Ownership percentage-Subsequent Event [Member]-BioTime, Inc. [Member] -->
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20170217_LegalEntityAxis_ParentCompanyMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF"> 0.5 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<!-- Ownership percentage-Subsequent Event [Member]-BioTime, Inc. [Member] --> <!-- Ownership percentage-BioTime, Inc. [Member] -->
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20151231_LegalEntityAxis_ParentCompanyMember" unitRef="U004" decimals="3"> 0.577 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<!-- Ownership percentage-BioTime, Inc. [Member] -->
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20161231_LegalEntityAxis_ParentCompanyMember" unitRef="U004" decimals="3"> 0.511 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<!-- Ownership percentage -->
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20160829" unitRef="U004" decimals="INF"> 0.512 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<!-- Ownership percentage-Minimum [Member]-Employee Stock Option [Member] -->
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U004" decimals="INF"> 0.1 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<!-- Ownership percentage-Maximum [Member]-BioTime, Inc. [Member]-Subsequent Event [Member] -->
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20170217_LegalEntityAxis_ParentCompanyMember_RangeAxis_MaximumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF"> 0.5 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<!-- Extinguishment of debt amount-Long-term Debt [Member]-Stock Purchase Subscription Agreement, First [Member]-BioTime, Inc. [Member] -->
<us-gaap:ExtinguishmentOfDebtAmount contextRef="c20150502to20150531_ExtinguishmentOfDebtAxis_LongTermDebtMember_LegalEntityAxis_ParentCompanyMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="-5"> 6600000 </us-gaap:ExtinguishmentOfDebtAmount>
<!-- Fair value measurements -->
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Fair value measurements</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Fair Value Measurements</font> (“ASC 820”). ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</div></div><div style="text-align: left;"> </div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 1</font> – Quoted prices in active markets for identical assets and liabilities.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 2</font> – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 3</font> – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div></div>
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<!-- Fair value of contingently issuable warrant -->
<us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 65000 </us-gaap:FairValueAdjustmentOfWarrants>
<!-- Fair value of contingently issuable warrant-Accumulated Deficit [Member] -->
<us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:FairValueAdjustmentOfWarrants>
<!-- Fair value of contingently issuable warrant-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:FairValueAdjustmentOfWarrants>
<!-- Fair value of contingently issuable warrant-Common Stock [Member] -->
<us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 65000 </us-gaap:FairValueAdjustmentOfWarrants>
<!-- Intangible assets, net -->
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20151231" unitRef="U001" decimals="-3"> 1230000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<!-- Intangible assets, net -->
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20161231" unitRef="U001" decimals="-3"> 988000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<!-- Finite-Lived Intangible Assets, Accumulated Amortization -->
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20151231" unitRef="U001" decimals="-3"> 1189000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<!-- Finite-Lived Intangible Assets, Accumulated Amortization -->
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20161231" unitRef="U001" decimals="-3"> 1431000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<!-- Finite-Lived Intangible Assets, Gross -->
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20151231" unitRef="U001" decimals="-3"> 2419000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<!-- Finite-Lived Intangible Assets, Gross -->
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20161231" unitRef="U001" decimals="-3"> 2419000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<!-- Intangible assets, useful life-Long-lived Intangible Assets [Member] -->
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20160101to20161231_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember"> P10Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<!-- Intangible assets, useful life -->
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20160101to20161231"> P10Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<!-- Gain (Loss) on Sale of Equity Investments -->
<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 569000 </us-gaap:GainLossOnSaleOfEquityInvestments>
<!-- Gain (Loss) on Sale of Equity Investments -->
<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 397000 </us-gaap:GainLossOnSaleOfEquityInvestments>
<!-- Gain (Loss) on Sale of Equity Investments -->
<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:GainLossOnSaleOfEquityInvestments>
<!-- Gain (loss) on extinguishment of debt-Long-term Debt [Member]-Stock Purchase Subscription Agreement, First [Member]-BioTime, Inc. [Member] -->
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c20150502to20150531_ExtinguishmentOfDebtAxis_LongTermDebtMember_LegalEntityAxis_ParentCompanyMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="0"> 0 </us-gaap:GainsLossesOnExtinguishmentOfDebt>
<!-- General and Administrative Expense -->
<us-gaap:GeneralAndAdministrativeExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 5463000 </us-gaap:GeneralAndAdministrativeExpense>
<!-- General and Administrative Expense -->
<us-gaap:GeneralAndAdministrativeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 4191000 </us-gaap:GeneralAndAdministrativeExpense>
<!-- General and Administrative Expense -->
<us-gaap:GeneralAndAdministrativeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 1011000 </us-gaap:GeneralAndAdministrativeExpense>
<!-- Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] -->
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Impairment of long-lived assets</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. Through 2016, there have been no such impairment losses.</div></div>
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<!-- Income Taxes -->
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">8. Income Taxes</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has filed standalone U.S. federal income tax returns since its inception. For California purposes, OncoCyte’s activity for 2015 and 2016 has been or will be included in BioTime’s California Combined tax return. The provision for income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The deferred tax assets, including the operating loss and credit carryforwards, generated by OncoCyte, will remain with OncoCyte.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The primary components of the deferred tax assets and liabilities at December 31, 2016 and 2015 were as follows (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Deferred liabilities:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Available-for-sale securities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(864</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total deferred tax liabilities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(864</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Deferred tax assets:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net operating loss carryforwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,730</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,139</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Research and development credit carryforwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,765</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,362</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Patents and fixed assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">179</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">136</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Stock-based compensation and accrued payroll</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,041</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">98</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Valuation Allowance</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(13,954</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,871</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total deferred tax assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">761</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">864</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net deferred tax asset (liability)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Due to losses incurred for all periods presented, OncoCyte did not record any provision or benefit for income taxes.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Computed tax benefit at federal statutory rate</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Permanent differences</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(9</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">State tax benefit</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Research and development credits</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Other</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Change in valuation allowance</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(44</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(45</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(34</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 61%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">As of December 31, 2016, OncoCyte has net operating loss carryforwards of approximately $30.6 million for U.S. federal income tax purposes and $15.1 million for state income tax purposes.  Federal net operating loss carryforwards expire from 2030 and 2036, and state carryforwards expire from 2029 and 2036. In addition, as of December 31, 2016, OncoCyte has research and development credit carryforwards for federal and state purposes of $860,000 and $905,000, respectively. The federal credits will expire between 2030 and 2036, while the state credits have no expiration.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">During 2015, OncoCyte sold 259,712 BioTime common shares, in at-the-market transactions which resulted in taxable gains of approximately $815,000. These taxable gains were fully offset by current operating losses, thus resulting in no income taxes due from the sales.  At December 31, 2016 and 2015, OncoCyte recorded deferred tax liabilities of $761,000 and $864,000 resulting from the difference in the tax basis of BioTime shares held as compared to the basis of those shares reported for financial reporting purposes (see Note 2).</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $5.1 million and $3.9 million for the years ended December 31, 2016 and 2015, respectively.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by net operating loss (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. There has not been a change in ownership for any of the periods presented.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. In general, OncoCyte is no longer subject to tax examination by major taxing authorities for years before 2011. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.</div></div>
</us-gaap:IncomeTaxDisclosureTextBlock>
<!-- Income Tax, Policy [Policy Text Block] -->
<us-gaap:IncomeTaxPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Income taxes</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte’s activity for 2015 and 2016 has been or will be included in BioTime’s California combined tax return. The provision for income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Income Taxes</font>, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. OncoCyte’s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If OncoCyte’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on OncoCyte’s statements of operations.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2016 and 2015. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2016 and 2015. OncoCyte is currently unaware of any tax issues under review.</div></div>
</us-gaap:IncomeTaxPolicyTextBlock>
<!-- Accounts payable and accrued liabilities -->
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 291000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<!-- Accounts payable and accrued liabilities -->
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 1042000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<!-- Accounts payable and accrued liabilities -->
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 229000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<!-- Increase (Decrease) in Due to Affiliates -->
<us-gaap:IncreaseDecreaseInDueToAffiliates contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 103000 </us-gaap:IncreaseDecreaseInDueToAffiliates>
<!-- Increase (Decrease) in Due to Affiliates -->
<us-gaap:IncreaseDecreaseInDueToAffiliates contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 111000 </us-gaap:IncreaseDecreaseInDueToAffiliates>
<!-- Increase (Decrease) in Due to Affiliates -->
<us-gaap:IncreaseDecreaseInDueToAffiliates contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> -115000 </us-gaap:IncreaseDecreaseInDueToAffiliates>
<!-- Increase (Decrease) in Due to Related Parties -->
<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 1672000 </us-gaap:IncreaseDecreaseInDueToRelatedParties>
<!-- Increase (Decrease) in Due to Related Parties -->
<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 1896000 </us-gaap:IncreaseDecreaseInDueToRelatedParties>
<!-- Increase (Decrease) in Due to Related Parties -->
<us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 2823000 </us-gaap:IncreaseDecreaseInDueToRelatedParties>
<!-- Increase (Decrease) in Prepaid Expense and Other Assets -->
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 274000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<!-- Increase (Decrease) in Prepaid Expense and Other Assets -->
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -6000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<!-- Increase (Decrease) in Prepaid Expense and Other Assets -->
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -101000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<!-- Long-lived intangible assets -->
<us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Long-lived intangible assets</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.</div></div>
</us-gaap:IntangibleAssetsFiniteLivedPolicy>
<!-- Interest Expense -->
<us-gaap:InterestExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 18000 </us-gaap:InterestExpense>
<!-- Interest Expense -->
<us-gaap:InterestExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:InterestExpense>
<!-- Interest Expense -->
<us-gaap:InterestExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:InterestExpense>
<!-- Interest expense, net -->
<us-gaap:InterestIncomeExpenseNet contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -2000 </us-gaap:InterestIncomeExpenseNet>
<!-- Interest expense, net -->
<us-gaap:InterestIncomeExpenseNet contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -28000 </us-gaap:InterestIncomeExpenseNet>
<!-- Interest expense, net -->
<us-gaap:InterestIncomeExpenseNet contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> -19000 </us-gaap:InterestIncomeExpenseNet>
<!-- Liabilities -->
<us-gaap:Liabilities contextRef="c20151231" unitRef="U001" decimals="-3"> 2314000 </us-gaap:Liabilities>
<!-- Liabilities -->
<us-gaap:Liabilities contextRef="c20161231" unitRef="U001" decimals="-3"> 4585000 </us-gaap:Liabilities>
<!-- Liabilities and Equity -->
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20161231" unitRef="U001" decimals="-3"> 14447000 </us-gaap:LiabilitiesAndStockholdersEquity>
<!-- Liabilities and Equity -->
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20151231" unitRef="U001" decimals="-3"> 12731000 </us-gaap:LiabilitiesAndStockholdersEquity>
<!-- Liabilities, Current -->
<us-gaap:LiabilitiesCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 2314000 </us-gaap:LiabilitiesCurrent>
<!-- Liabilities, Current -->
<us-gaap:LiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 4275000 </us-gaap:LiabilitiesCurrent>
<!-- Stated floating annual interest rate-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="3"> 0.045 </us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
<!-- Line of Credit Facility, Maximum Borrowing Capacity-Silicon Valley Bank [Member]-Subsequent Event [Member] -->
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-6"> 2000000 </us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<!-- Long-term Debt-BioTime, Inc. [Member]-Stock Purchase Subscription Agreement, First [Member]-Common Stock [Member] -->
<us-gaap:LongTermDebt contextRef="c20150531_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="-5"> 3300000 </us-gaap:LongTermDebt>
<!-- Accounting for BioTime shares -->
<us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Accounting for BioTime shares</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Investments – Debt and Equity Securities</font>, as the shares have a readily determinable fair value quoted on the NYSE MKT and are held principally for sale to meet future working capital needs. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. Realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to equity in common stock consistent with, and pursuant to, ASC 805-50, transactions between entities under common control.  As discussed in Note 10, on February 17, 2017 BioTime deconsolidated our financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having “control” over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares after February 17, 2017 will be included in its statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As discussed in Note 10, on February 17, 2017, as a result of a loss of control experienced by BioTime on OncoCyte due to BioTime’s reduced ownership to below 50% of OncoCyte outstanding common stock, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. Due to this deconsolidation and BioTime no longer having a controlling financial interest in OncoCyte’s operations and financial statements, any realized gains and losses OncoCyte generates from the sale of BioTime shares, beginning on February 17, 2017, will be included in OncoCyte’s statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2016, OncoCyte held 619,706 BioTime common shares as available-for-sale securities with a fair market value of $2.2 million.</div></div>
</us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy>
<!-- Money Market Funds, at Carrying Value -->
<us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c20161231" unitRef="U001" decimals="-5"> 9400000 </us-gaap:MoneyMarketFundsAtCarryingValue>
<!-- Net Cash Provided by (Used in) Investing Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -181000 </us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Investing Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 315000 </us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Investing Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 1320000 </us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Financing Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 9881000 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Financing Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 11653000 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Financing Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Operating Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> -4229000 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Operating Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -1164000 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<!-- Net Cash Provided by (Used in) Operating Activities, Continuing Operations -->
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -7522000 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<!-- Net Income (Loss) Attributable to Parent -->
<us-gaap:NetIncomeLoss contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> -8735000 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent -->
<us-gaap:NetIncomeLoss contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -4986000 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent -->
<us-gaap:NetIncomeLoss contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -11168000 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Common Stock [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 0 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Accumulated Deficit [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> -11168000 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Accumulated Deficit [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> -8735000 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Accumulated Deficit [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> -4986000 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Common Stock [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 0 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:NetIncomeLoss>
<!-- Net Income (Loss) Attributable to Parent-Common Stock [Member] -->
<us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 0 </us-gaap:NetIncomeLoss>
<!-- New Accounting Pronouncements, Policy [Policy Text Block] -->
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Recent accounting pronouncements</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In May 2014, the FASB issued ASU 2014-09, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Revenue from Contracts with Customers (Topic 606)</font>, which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">In April 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”. The amendments clarify two aspects of Topic 606: (a) identifying performance obligations; and (b) the licensing implementation guidance. The update is effective for annual periods beginning after December 15, 2017 including interim reporting periods therein.  OncoCyte does not expect the adoption of ASC 606 will have a material impact on its financial statements.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"> </div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte’s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2016.  OncoCyte is currently evaluating the impact the adoption of ASU 2016-09 will have on its financial statements.</div></div></div>
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<!-- Nonoperating Income (Expense) -->
<us-gaap:NonoperatingIncomeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> -17000 </us-gaap:NonoperatingIncomeExpense>
<!-- Nonoperating Income (Expense) -->
<us-gaap:NonoperatingIncomeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -13000 </us-gaap:NonoperatingIncomeExpense>
<!-- Nonoperating Income (Expense) -->
<us-gaap:NonoperatingIncomeExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -28000 </us-gaap:NonoperatingIncomeExpense>
<!-- Number of Operating Segments -->
<us-gaap:NumberOfOperatingSegments contextRef="c20160101to20161231" unitRef="U005" decimals="INF"> 1 </us-gaap:NumberOfOperatingSegments>
<!-- Operating Expenses -->
<us-gaap:OperatingExpenses contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 4973000 </us-gaap:OperatingExpenses>
<!-- Operating Expenses -->
<us-gaap:OperatingExpenses contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 11140000 </us-gaap:OperatingExpenses>
<!-- Operating Expenses -->
<us-gaap:OperatingExpenses contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 8718000 </us-gaap:OperatingExpenses>
<!-- Operating Loss Carryforwards-State [Member] -->
<us-gaap:OperatingLossCarryforwards contextRef="c20161231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="-5"> 15100000 </us-gaap:OperatingLossCarryforwards>
<!-- Operating Loss Carryforwards-Federal [Member] -->
<us-gaap:OperatingLossCarryforwards contextRef="c20161231_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="U001" decimals="-5"> 30600000 </us-gaap:OperatingLossCarryforwards>
<!-- Operating Income (Loss) -->
<us-gaap:OperatingIncomeLoss contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> -8718000 </us-gaap:OperatingIncomeLoss>
<!-- Operating Income (Loss) -->
<us-gaap:OperatingIncomeLoss contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -4973000 </us-gaap:OperatingIncomeLoss>
<!-- Operating Income (Loss) -->
<us-gaap:OperatingIncomeLoss contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -11140000 </us-gaap:OperatingIncomeLoss>
<!-- Operating loss carryforwards, expiration date-Federal [Member]-Minimum [Member] -->
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20160101to20161231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MinimumMember"> 2030-12-31 </us-gaap:OperatingLossCarryforwardsExpirationDate>
<!-- Operating loss carryforwards, expiration date-Maximum [Member]-State [Member] -->
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20160101to20161231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MaximumMember"> 2036-12-31 </us-gaap:OperatingLossCarryforwardsExpirationDate>
<!-- Operating loss carryforwards, expiration date-Minimum [Member]-State [Member] -->
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20160101to20161231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MinimumMember"> 2029-12-31 </us-gaap:OperatingLossCarryforwardsExpirationDate>
<!-- Operating loss carryforwards, expiration date-Federal [Member]-Maximum [Member] -->
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20160101to20161231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MaximumMember"> 2036-12-31 </us-gaap:OperatingLossCarryforwardsExpirationDate>
<!-- Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] -->
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">1. Organization, Description of the Business and Liquidity</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte Corporation (“OncoCyte”) was incorporated in 2009 in the state of California and at December 31, 2016 was a majority-owned subsidiary of BioTime, Inc. (“BioTime”), a publicly traded biotechnology company focused in the field of regenerative medicine. As discussed in Note 10, effective February 17, 2017, OncoCyte ceased to be a subsidiary of BioTime for financial reporting purposes when BioTime’s percentage ownership of outstanding OncoCyte common stock declined below 50% as a result of the issuance of additional OncoCyte common stock to certain investors who exercised OncoCyte stock purchase warrants.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers broadly expressed in numerous types of cancer. OncoCyte is presently focusing its efforts on developing diagnostic tests for use in detecting a variety of cancers including lung, bladder, and breast cancers.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Liquidity</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">For all periods presented, OncoCyte had generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants to its shareholders, including BioTime, loans from BioTime and other BioTime affiliates, warrant exercises, and a bank loan (see Note 10), and sales of BioTime common shares that OncoCyte held as available-for-sale securities (see Note 2). OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $35.3 million and $24.1 million as December 31, 2016 and 2015, respectively.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte’s research and development efforts are successful to the point where it believes that a commercial product can be launched successfully, then additional capital will be required for developing a sales and marketing team and launching OncoCyte’s first diagnostic test.  Dependent on results of any product commercialization and ongoing sales, if any, additional capital might be required in 2017 or beyond to develop and launch products, for working capital, and for other expenses. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016, we had $10.2 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $2.2 million.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 17, 2017, OncoCyte received cash proceeds of $2.0 million when certain investors exercised 625,000 warrants to purchase OncoCyte common stock at an exercise price of $3.25 per share. The warrants had been issued as part of a financing that was completed on August 29, 2016, through which OncoCyte sold an aggregate of 3,246,153 immediately separable “units”, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (see Note 10).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 21, 2017, OncoCyte entered into a Loan and Security Agreement with Silicon Valley Bank for a working capital loan of $2 million, collateralized by substantially all of OncoCyte’s assets other than intellectual property such as patents and trade secrets that OncoCyte owns (see Note 10).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">Based on cash and cash equivalents currently on hand, including the warrant exercises and working capital loan under the Loan Agreement discussed above and in Note 10, OncoCyte believes it has sufficient cash, cash equivalents, available for sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein (see Note 2).</div></div>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<!-- Realized loss on sale of BioTime shares -->
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 569000 </us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<!-- Realized loss on sale of BioTime shares -->
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<!-- Realized loss on sale of BioTime shares -->
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 397000 </us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<!-- Other Assets, Current -->
<us-gaap:OtherAssetsCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 22000 </us-gaap:OtherAssetsCurrent>
<!-- Other Assets, Current -->
<us-gaap:OtherAssetsCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 103000 </us-gaap:OtherAssetsCurrent>
<!-- Unrealized (loss) gain on BioTime shares held as available-for-sale securities -->
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -21000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<!-- Unrealized (loss) gain on BioTime shares held as available-for-sale securities -->
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 75000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<!-- Unrealized (loss) gain on BioTime shares held as available-for-sale securities -->
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -304000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<!-- Other Nonoperating Income (Expense) -->
<us-gaap:OtherNonoperatingIncomeExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:OtherNonoperatingIncomeExpense>
<!-- Other Nonoperating Income (Expense) -->
<us-gaap:OtherNonoperatingIncomeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 2000 </us-gaap:OtherNonoperatingIncomeExpense>
<!-- Other Nonoperating Income (Expense) -->
<us-gaap:OtherNonoperatingIncomeExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> -11000 </us-gaap:OtherNonoperatingIncomeExpense>
<!-- Payments of Stock Issuance Costs -->
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 773000 </us-gaap:PaymentsOfStockIssuanceCosts>
<!-- Payments of Stock Issuance Costs -->
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:PaymentsOfStockIssuanceCosts>
<!-- Payments of Stock Issuance Costs -->
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:PaymentsOfStockIssuanceCosts>
<!-- Payments to Acquire Property, Plant, and Equipment -->
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 9000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<!-- Payments to Acquire Property, Plant, and Equipment -->
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 500000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<!-- Payments to Acquire Property, Plant, and Equipment -->
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 106000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<!-- Preferred stock, shares issued (in shares) -->
<us-gaap:PreferredStockSharesIssued contextRef="c20161231" unitRef="U002" decimals="-3"> 0 </us-gaap:PreferredStockSharesIssued>
<!-- Preferred stock, shares issued (in shares) -->
<us-gaap:PreferredStockSharesIssued contextRef="c20151231" unitRef="U002" decimals="-3"> 0 </us-gaap:PreferredStockSharesIssued>
<!-- Preferred stock, shares issued (in shares) --> <!-- Preferred stock, par value (in dollars per share) -->
<us-gaap:PreferredStockNoParValue contextRef="c20161231" unitRef="U003" decimals="INF"> 0 </us-gaap:PreferredStockNoParValue>
<!-- Preferred stock, par value (in dollars per share) -->
<us-gaap:PreferredStockNoParValue contextRef="c20151231" unitRef="U003" decimals="INF"> 0 </us-gaap:PreferredStockNoParValue>
<!-- Preferred stock, shares authorized (in shares) -->
<us-gaap:PreferredStockSharesAuthorized contextRef="c20161231" unitRef="U002" decimals="-3"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<!-- Preferred stock, shares authorized (in shares) -->
<us-gaap:PreferredStockSharesAuthorized contextRef="c20151231" unitRef="U002" decimals="-3"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<!-- Preferred stock, shares outstanding (in shares) -->
<us-gaap:PreferredStockSharesOutstanding contextRef="c20161231" unitRef="U002" decimals="-3"> 0 </us-gaap:PreferredStockSharesOutstanding>
<!-- Preferred stock, shares outstanding (in shares) --> <!-- Preferred stock, shares outstanding (in shares) -->
<us-gaap:PreferredStockSharesOutstanding contextRef="c20151231" unitRef="U002" decimals="-3"> 0 </us-gaap:PreferredStockSharesOutstanding>
<!-- Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding -->
<us-gaap:PreferredStockValue contextRef="c20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:PreferredStockValue>
<!-- Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding -->
<us-gaap:PreferredStockValue contextRef="c20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:PreferredStockValue>
<!-- Insurance -->
<us-gaap:PrepaidInsurance contextRef="c20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:PrepaidInsurance>
<!-- Insurance -->
<us-gaap:PrepaidInsurance contextRef="c20161231" unitRef="U001" decimals="-3"> 182000 </us-gaap:PrepaidInsurance>
<!-- Prepaid expenses and other current assets -->
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 388000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<!-- Prepaid expenses and other current assets -->
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 285000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<!-- Proceeds from Issuance of Common Stock -->
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<!-- Proceeds from Issuance of Common Stock -->
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<!-- Proceeds from Issuance of Common Stock -->
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 11649000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<!-- Proceeds from Issuance of Common Stock-Stock Purchase Subscription Agreement, First [Member]-Common Stock [Member]-BioTime, Inc. [Member] -->
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150901to20150930_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="-5"> 8300000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<!-- Proceeds from Issuance of Common Stock-Stock Purchase Subscription Agreement, First [Member]-Common Stock [Member]-Investors [Member] -->
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150502to20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U001" decimals="-5"> 3300000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<!-- Proceeds from sale of BioTime shares -->
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 1329000 </us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
<!-- Proceeds from sale of BioTime shares -->
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 815000 </us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
<!-- Proceeds from sale of BioTime shares -->
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
<!-- Proceeds from exercise of options -->
<us-gaap:ProceedsFromStockOptionsExercised contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 4000 </us-gaap:ProceedsFromStockOptionsExercised>
<!-- Proceeds from exercise of options -->
<us-gaap:ProceedsFromStockOptionsExercised contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:ProceedsFromStockOptionsExercised>
<!-- Proceeds from exercise of options -->
<us-gaap:ProceedsFromStockOptionsExercised contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 218000 </us-gaap:ProceedsFromStockOptionsExercised>
<!-- Equipment and furniture, useful life-Minimum [Member]-Equipment and Furniture [Member] -->
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MinimumMember"> P3Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<!-- Equipment and furniture, useful life-Equipment and Furniture [Member]-Maximum [Member] -->
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MaximumMember"> P10Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<!-- Equipment and furniture, useful life-Minimum [Member]-Equipment [Member] -->
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember"> P3Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<!-- Equipment and furniture, useful life-Equipment [Member]-Maximum [Member] -->
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20160101to20161231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember"> P5Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<!-- Property, Plant and Equipment, Policy [Policy Text Block] -->
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Equipment and furniture</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years.  For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte’s results of operations.</div></div>
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<!-- Property, Plant and Equipment [Table Text Block] -->
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, equipment and furniture were comprised of the following (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Equipment and furniture</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,007</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accumulated depreciation</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(319</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(174</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Equipment and furniture, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">688</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">576</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>
</us-gaap:PropertyPlantAndEquipmentTextBlock>
<!-- Equipment and furniture, net -->
<us-gaap:PropertyPlantAndEquipmentNet contextRef="c20151231" unitRef="U001" decimals="-3"> 576000 </us-gaap:PropertyPlantAndEquipmentNet>
<!-- Equipment and furniture, net -->
<us-gaap:PropertyPlantAndEquipmentNet contextRef="c20161231" unitRef="U001" decimals="-3"> 688000 </us-gaap:PropertyPlantAndEquipmentNet>
<!-- Property, Plant and Equipment, Gross -->
<us-gaap:PropertyPlantAndEquipmentGross contextRef="c20151231" unitRef="U001" decimals="-3"> 750000 </us-gaap:PropertyPlantAndEquipmentGross>
<!-- Property, Plant and Equipment, Gross -->
<us-gaap:PropertyPlantAndEquipmentGross contextRef="c20161231" unitRef="U001" decimals="-3"> 1007000 </us-gaap:PropertyPlantAndEquipmentGross>
<!-- Related Party Transactions Disclosure [Text Block] -->
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">4. Related Party Transactions</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Shared Facilities and Service Agreement</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On October 8, 2009, OncoCyte and BioTime executed a Shared Facilities and Services Agreement (“Shared Facilities Agreement”). Under the terms of the Shared Facilities Agreement, BioTime will allow OncoCyte to use its premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime will also provide accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime will also provide OncoCyte with the services of its laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">BioTime charges OncoCyte a Use Fee for services received and usage of facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates costs incurred, as applicable, to OncoCyte, such costs include services of Bio Time employees, equipment, insurance, lease, professional, software, supplies and utilities. Allocation depends on key cost drivers including actual documented use, square footage of facilities used, time spent, costs incurred by or for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime (collectively “Use Fees”). BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime has not elected to charge this markup since the inception of the Shared Facilities Agreement and through the end of 2015.  Beginning in 2016, BioTime commenced charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through December 31, 2016 BioTime has not charged OncoCyte any interest.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. Furthermore, BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers thereof to invoice OncoCyte directly.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement otherwise is terminated under another provision of the agreement.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In the aggregate, BioTime allocated and charged such Use Fees to OncoCyte approximating $790,000, $595,000 and $344,000 included in general and administrative expenses, and $691,000, $565,000 and $552,000 included in research and development expenses included in the statements of operations during the years ended December 31, 2016, 2015 and 2014, respectively.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2016 and 2015, OncoCyte had $2.9 million and $847,000 outstanding and payable to BioTime and affiliates included in current liabilities in connection with the costs incurred under the Shared Facilities Agreement. Since these amounts are due and payable in 30 days of being invoiced, the payables are classified as current liabilities for all periods presented.</div></div>
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<!-- Repayments of Long-term Capital Lease Obligations -->
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<!-- Repayments of Long-term Capital Lease Obligations -->
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 0 </us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<!-- Repayments of Long-term Capital Lease Obligations -->
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 114000 </us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<!-- Research and Development Expense -->
<us-gaap:ResearchAndDevelopmentExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 4527000 </us-gaap:ResearchAndDevelopmentExpense>
<!-- Research and Development Expense -->
<us-gaap:ResearchAndDevelopmentExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 5677000 </us-gaap:ResearchAndDevelopmentExpense>
<!-- Research and Development Expense -->
<us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 3962000 </us-gaap:ResearchAndDevelopmentExpense>
<!-- Research and Development Expense, Policy [Policy Text Block] -->
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Research and development expenses</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, and expenses for outside consultants. These expenses include both direct and allocated or indirect overhead costs allocated by BioTime (see Note 4). Research and development costs are expensed as incurred.</div></div>
</us-gaap:ResearchAndDevelopmentExpensePolicy>
<!-- Accumulated deficit -->
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20151231" unitRef="U001" decimals="-3"> -24134000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<!-- Accumulated deficit -->
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20161231" unitRef="U001" decimals="-3"> -35302000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value-Employee Stock Option [Member]-Maximum [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U001" decimals="0"> 100000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 2000000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
<!-- Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 1.83 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 85000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 566000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<!-- Expected life-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember"> P6Y9M29D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<!-- Expected life-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember"> P6Y2M16D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<!-- Expected life-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" id="Item-1"> P0Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 639000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 1757000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares-Employee Stock Option [Member] -->
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 880000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<!-- Proceeds from sale of stock-BioTime, Inc. [Member]-Subsequent Event [Member] -->
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c20170217to20170217_LegalEntityAxis_ParentCompanyMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5"> 2000000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<!-- Proceeds from sale of stock -->
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c20160829to20160829" unitRef="U001" decimals="-4"> 9800000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<!-- Proceeds from sale of stock-Subsequent Event [Member] -->
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c20170217to20170217_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5"> 2000000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<!-- Components of Deferred Tax Assets and Liabilities -->
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The primary components of the deferred tax assets and liabilities at December 31, 2016 and 2015 were as follows (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Deferred liabilities:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Available-for-sale securities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(864</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total deferred tax liabilities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(864</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Deferred tax assets:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net operating loss carryforwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,730</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">8,139</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Research and development credit carryforwards</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,765</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,362</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Patents and fixed assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">179</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">136</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Stock-based compensation and accrued payroll</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,041</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">98</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Valuation Allowance</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(13,954</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,871</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total deferred tax assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">761</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">864</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net deferred tax asset (liability)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<!-- Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] -->
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 64%;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">for</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Grant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Options </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Outstanding</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Price</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total at January 1, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">639</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,361</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.52</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Increase in option pool</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,000</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options granted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,448</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,448</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.21</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options exercised</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options forfeited or cancelled</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">566</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(566</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.59</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total at December 31, 2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,757</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.03</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options granted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(962</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">962</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.58</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options exercised</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(100</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.19</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Options forfeited, cancelled or expired</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">85</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(85</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 3%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.00</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total at December 31, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">880</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.52</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Exercisable at December 31, 2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 6%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,591</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.83</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 3%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<!-- Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] -->
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The assumptions that were used to calculate the grant date fair value of OncoCyte’s employee and non-employee stock option grants for the years ended December 31, 2016, 2015 and 2014 were as follows.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014<font style="font-size: 10pt; font-family: 'Times New Roman';"><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">(1)</sup></font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Expected life (in years)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6.21</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6.83</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Risk-free interest rates</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.46</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.87</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Volatility</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">64.64</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">74.15</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Dividend yield</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr></table><div style="text-align: justify;"> </div><div style="text-align: justify; margin-left: 45pt;"><hr align="left" noshade="noshade" style="border-top: medium none; height: 2px; border-right: medium none; border-bottom: medium none; color: #000000; text-align: left; margin-left: 0px; border-left: medium none; width: 90%; background-color: #000000; margin-right: auto;" /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; vertical-align: top; width: 18pt; align: right;">(1)</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';">No stock options were granted in 2014.</div></td></tr></table></div></div>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<!-- Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock -->
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2016, 2015 and 2014 because including them would have been antidilutive (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Stock options under Stock Option Plan</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,361</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,246</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div>
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<!-- Computations of Basic and Diluted Net Loss Per Share -->
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The computations of basic and diluted net loss per common share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share amounts):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net loss</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(11,168</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,735</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4,986</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Weighted average common shares outstanding – basic and diluted</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,529</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,009</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">18,200</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net loss per common share – basic and diluted</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.27</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr></table></div>
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<!-- Schedule of Finite-Lived Intangible Assets [Table Text Block] -->
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, intangible assets were comprised of the following (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accumulated amortization</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,431</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,189</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Intangible assets, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">988</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,230</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<!-- Income Tax Reconciliation -->
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Computed tax benefit at federal statutory rate</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Permanent differences</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(9</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">State tax benefit</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Research and development credits</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #ffffff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Other</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Change in valuation allowance</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(44</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(45</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(34</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.07%; background-color: #ffffff;">%)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 61%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 4.07%; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr></table></div>
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<!-- Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] -->
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2016, 2015 and 2014 (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Research and development</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">312</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">456</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">177</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">General and administrative</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">610</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.07%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,359</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.07%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">141</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.07%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Total stock-based compensation expense</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">922</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,815</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">318</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.07%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<!-- Segments -->
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Segments</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, OncoCyte’s executive management team has viewed OncoCyte’s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte’s sole operating segment.</div></div>
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<!-- General and administrative expenses -->
<us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">General and administrative expenses</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte’s general and administrative expenses relate primarily to compensation and related benefits, including stock-based compensation, for executive and corporate personnel, including direct costs and costs allocated by BioTime; professional and consulting fees; direct overhead and indirect overhead allocated by BioTime (see Note 4).</div></div>
</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
<!-- Stock options exercise price (in dollars per share)-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 2.21 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<!-- Stock options exercise price (in dollars per share)-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 3.58 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<!-- Stock options exercise price (in dollars per share)-Employees [Member]-Subsequent Event [Member] -->
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20170217to20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_EmployeesMember" unitRef="U003" decimals="2"> 4.70 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period-Employee Stock Option [Member]-Maximum [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"> P5Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<!-- Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 2.19 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<!-- Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 1.34 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<!-- Stock options granted (in shares)-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 1448000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<!-- Stock options granted (in shares)-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 962000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<!-- Stock options granted (in shares)-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<!-- Stock options granted (in shares)-Employees [Member]-Subsequent Event [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20170217to20170217_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_EmployeesMember" unitRef="U002" decimals="INF"> 357130 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<!-- Issue price per share (in dollars per share)-Stock Purchase Subscription Agreement, First [Member]-Common Stock [Member]-Investors [Member] -->
<us-gaap:SharePrice contextRef="c20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U003" decimals="INF"> 2.20 </us-gaap:SharePrice>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized-Stock Option Plan 2010 [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c20151231_PlanNameAxis_StockOptionPlan2010Member" unitRef="U002" decimals="INF"> 2000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4"> 0.0146 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4"> 0.0187 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0" id="Item-2"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 566000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 85000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0" id="Item-3"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20140101to20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0" id="Item-4"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4"> 0.7415 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4"> 0.6464 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 1.52 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 2.52 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 2.03 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20141231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 1361000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 3017000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 2240000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 1.59 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
<!-- Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options-Employee Stock Option [Member] -->
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 1591000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<!-- Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] -->
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Stock-based compensation</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Compensation – Stock Compensation</font> (“ASC 718”).</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures, over the requisite service period. OncoCyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under OncoCyte’s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis, net of estimated forfeitures, over the requisite service period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Equity-Based Payments to Non-Employees</font>. Stock option awards issued to non-employees, principally consultants and employees of BioTime or employees of BioTime subsidiaries who perform services for OncoCyte, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. OncoCyte records compensation expense based on the then-current fair values of the stock options at each financial reporting date. Compensation expense recorded during the service period is adjusted in subsequent periods for changes in the fair value of the stock options until the earlier of the date at which the non-employee’s performance is complete or a performance commitment is reached, which is generally when the stock option award vests. Compensation expense for non-employee grants is recorded on a straight-line basis in the statements of operations.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7).</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there was no public market for OncoCyte’s common stock prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Valuation of Privately Held Company Equity Securities Issued As Compensation</font>.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the “simplified method” provided under<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Staff Accounting Bulletin, Topic 14</font>, or SAB Topic 14.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Because OncoCyte’s common stock had no public trading history prior to December 31, 2015, for the years ended December 31, 2015 and 2014, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the year ended December 31, 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies. OncoCyte determined the expected volatility assumption using the frequency of daily historical prices of comparable public company’s common stock for a period equal to the expected term of the options.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte’s stock options.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The dividend yield assumption is based on OncoCyte’s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.</div></div>
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<!-- Significant Accounting Policies [Text Block] -->
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2. Summary of Significant Accounting Policies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Basis of presentation</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (“GAAP”). BioTime has consolidated the results of OncoCyte into BioTime’s consolidated results based on BioTime’s ability to control OncoCyte’s operating and financial decisions and policies through its majority ownership of OncoCyte common stock throughout the periods presented. BioTime owned 51.1% and 57.7% of the outstanding common stock of OncoCyte at December 31, 2016 and 2015, respectively.  As more fully discussed in Note 10, on February 17, 2017, BioTime’s percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of “control,” of OncoCyte as under GAAP and a result, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP as of February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime’s retained share ownership in OncoCyte which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte’s operations or management. Management evaluates the appropriateness of the percentage allocations on a quarterly basis and believes that this basis for allocation is reasonable.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Reverse stock split</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Use of estimates</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to going concern assessment of OncoCyte financial statements, the allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Going concern assessment</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">With the implementation of FASB’s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte will assess going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div><div style="text-align: justify;"> </div><div style="text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Fair value measurements</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Fair Value Measurements</font> (“ASC 820”). ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</div></div><div style="text-align: left;"> </div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 1</font> – Quoted prices in active markets for identical assets and liabilities.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 2</font> – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 3</font> – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Cash and cash equivalents</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2016 and 2015, OncoCyte's cash balances totaled $10.2 million and $8.0 million, respectively, and consist of bank account deposits and $9.4 million held in money market funds at December 31, 2016.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Accounting for BioTime shares</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Investments – Debt and Equity Securities</font>, as the shares have a readily determinable fair value quoted on the NYSE MKT and are held principally for sale to meet future working capital needs. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. Realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to equity in common stock consistent with, and pursuant to, ASC 805-50, transactions between entities under common control.  As discussed in Note 10, on February 17, 2017 BioTime deconsolidated our financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having “control” over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares after February 17, 2017 will be included in its statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As discussed in Note 10, on February 17, 2017, as a result of a loss of control experienced by BioTime on OncoCyte due to BioTime’s reduced ownership to below 50% of OncoCyte outstanding common stock, BioTime deconsolidated OncoCyte’s financial statements from BioTime’s consolidated financial statements. Due to this deconsolidation and BioTime no longer having a controlling financial interest in OncoCyte’s operations and financial statements, any realized gains and losses OncoCyte generates from the sale of BioTime shares, beginning on February 17, 2017, will be included in OncoCyte’s statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2016, OncoCyte held 619,706 BioTime common shares as available-for-sale securities with a fair market value of $2.2 million.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Long-lived intangible assets</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Equipment and furniture</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years.  For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte’s results of operations.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Impairment of long-lived assets</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. Through 2016, there have been no such impairment losses.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Accounting for warrants</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</font><font style="font-size: 10pt; font-family: 'Times New Roman';">, then in accordance with ASC 815-40,</font><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</font><font style="font-size: 10pt; font-family: 'Times New Roman';">.  Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares.  If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature.  If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP.  After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity.  Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations.  Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Income taxes</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte’s activity for 2015 and 2016 has been or will be included in BioTime’s California combined tax return. The provision for income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Income Taxes</font>, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. OncoCyte’s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If OncoCyte’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on OncoCyte’s statements of operations.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2016 and 2015. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2016 and 2015. OncoCyte is currently unaware of any tax issues under review.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Research and development expenses</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, and expenses for outside consultants. These expenses include both direct and allocated or indirect overhead costs allocated by BioTime (see Note 4). Research and development costs are expensed as incurred.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">General and administrative expenses</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte’s general and administrative expenses relate primarily to compensation and related benefits, including stock-based compensation, for executive and corporate personnel, including direct costs and costs allocated by BioTime; professional and consulting fees; direct overhead and indirect overhead allocated by BioTime (see Note 4).</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Stock-based compensation</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Compensation – Stock Compensation</font> (“ASC 718”).</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures, over the requisite service period. OncoCyte uses the Black-Scholes option pricing model for estimating the fair value of options granted under OncoCyte’s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis, net of estimated forfeitures, over the requisite service period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Equity-Based Payments to Non-Employees</font>. Stock option awards issued to non-employees, principally consultants and employees of BioTime or employees of BioTime subsidiaries who perform services for OncoCyte, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. OncoCyte records compensation expense based on the then-current fair values of the stock options at each financial reporting date. Compensation expense recorded during the service period is adjusted in subsequent periods for changes in the fair value of the stock options until the earlier of the date at which the non-employee’s performance is complete or a performance commitment is reached, which is generally when the stock option award vests. Compensation expense for non-employee grants is recorded on a straight-line basis in the statements of operations.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7).</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there was no public market for OncoCyte’s common stock prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Valuation of Privately Held Company Equity Securities Issued As Compensation</font>.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the “simplified method” provided under<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Staff Accounting Bulletin, Topic 14</font>, or SAB Topic 14.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Because OncoCyte’s common stock had no public trading history prior to December 31, 2015, for the years ended December 31, 2015 and 2014, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the year ended December 31, 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies. OncoCyte determined the expected volatility assumption using the frequency of daily historical prices of comparable public company’s common stock for a period equal to the expected term of the options.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte’s stock options.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The dividend yield assumption is based on OncoCyte’s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Net loss per common share</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The computations of basic and diluted net loss per common share for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands, except per share amounts):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net loss</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(11,168</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,735</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4,986</div></td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Weighted average common shares outstanding – basic and diluted</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,529</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,009</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">18,200</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Net loss per common share – basic and diluted</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.27</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 3.74%; background-color: #cceeff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr></table><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2016, 2015 and 2014 because including them would have been antidilutive (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 61%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Stock options under Stock Option Plan</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,361</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 61%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,246</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 3.74%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Segments</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, OncoCyte’s executive management team has viewed OncoCyte’s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte’s sole operating segment.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Recent accounting pronouncements</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In May 2014, the FASB issued ASU 2014-09, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Revenue from Contracts with Customers (Topic 606)</font>, which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">In April 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”. The amendments clarify two aspects of Topic 606: (a) identifying performance obligations; and (b) the licensing implementation guidance. The update is effective for annual periods beginning after December 15, 2017 including interim reporting periods therein.  OncoCyte does not expect the adoption of ASC 606 will have a material impact on its financial statements.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"> </div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte’s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2016.  OncoCyte is currently evaluating the impact the adoption of ASU 2016-09 will have on its financial statements.</div></div></div>
</us-gaap:SignificantAccountingPoliciesTextBlock>
<!-- Stock-based compensation-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 922000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Common Stock [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 922000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Accumulated Deficit [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Common Stock [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 1815000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Accumulated Deficit [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Accumulated Deficit [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation-Common Stock [Member] -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 318000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 318000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Stock-based compensation -->
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 1815000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<!-- Exercise of stock options -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 218000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Exercise of stock options-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Exercise of stock options-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Exercise of stock options-Common Stock [Member] -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 4000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Exercise of stock options-Common Stock [Member] -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 218000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Exercise of stock options -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 4000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Exercise of stock options-Accumulated Deficit [Member] -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Exercise of stock options-Accumulated Deficit [Member] -->
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<!-- Stock Issued During Period, Shares, New Issues-Stock Purchase Subscription Agreement, First [Member]-Common Stock [Member]-Investors [Member] -->
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150502to20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U002" decimals="INF"> 1500000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<!-- Stock Issued During Period, Shares, New Issues-Stock Purchase Subscription Agreement, First [Member]-Common Stock [Member]-BioTime, Inc. [Member] -->
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20150901to20150930_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U002" decimals="INF"> 2710857 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<!-- Exercise of stock options (in shares)-Common Stock [Member] -->
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 100000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<!-- Exercise of stock options (in shares)-Common Stock [Member] -->
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 3000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<!-- Exercise of stock options (in shares)-Employee Stock Option [Member] -->
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 100000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<!-- Exercise of stock options (in shares)-Employee Stock Option [Member] -->
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 3000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<!-- Stockholders' Equity Note, Stock Split, Conversion Ratio -->
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c20151118to20151118" unitRef="U004" decimals="1"> 0.5 </us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<!-- Stockholders' Equity Note Disclosure [Text Block] -->
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">6. Shareholders’ Equity</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Preferred Stock</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte is authorized to issue up to 5,000,000 shares of no par value preferred stock. As of December 31, 2016, no preferred shares were issued or outstanding.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Common Stock</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has up to 50,000,000 shares of no par value common stock authorized. The holders of OncoCyte’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of OncoCyte common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of OncoCyte outstanding preferred shares, if any.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of OncoCyte stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Issuance of Common Stock</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In May 2015, OncoCyte entered into Subscription Agreements with Bio Time and two other shareholders (“Investors”). Under the Subscription Agreements, OncoCyte issued 1,500,000 shares of common stock to the Investors for $3.3 million cash, or $2.20 per share. Concurrently, BioTime purchased 1,500,000 shares of OncoCyte common stock in exchange for the cancellation of $3.3 million of indebtedness owed to BioTime by OncoCyte (see Note 5).</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">During September 2015, OncoCyte entered into a Subscription Agreement with BioTime pursuant to which BioTime purchased 2,710,857 shares of OncoCyte common stock for $8.3 million in cash, as part of a subscription offer made to all OncoCyte shareholders on a pro rata basis.</div><div style="text-align: left; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On December 31, 2015, in connection with BioTime’s distribution of OncoCyte common stock to BioTime shareholders, on a pro rata basis, OncoCyte received 30,985 shares of its own common stock from BioTime as a dividend in kind. <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">On that date, BioTime shareholders, including OncoCyte, received one share of OncoCyte common stock for every twenty shares of BioTime common stock held. The OncoCyte common stock distributed to OncoCyte was immediately retired on that date and reverted to the status of authorized but unissued common stock.</font></div><div style="text-align: justify;"> </div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Issuance of Common Stock and Warrants</div><div><br /></div></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On August 29, 2016, OncoCyte sold an aggregate of 3,246,153 immediately separable units, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (the “Offering Warrants”), at a price of $3.25 per unit (the “Offering”). The sales were made pursuant to the terms and conditions of certain Purchase Agreements between OncoCyte and the purchasers in the Offering. The purchasers included certain OncoCyte existing shareholders other than BioTime. At the close of the Offering, <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">BioTime’s percentage ownership of the outstanding common stock of OncoCyte declined to 51.2% through which BioTime retained a controlling interest in OncoCyte</font>. OncoCyte received $9.8 million in net proceeds after discounts, commissions and expenses from the Offering. OncoCyte will use the proceeds from the Offering for funding its operations or for working capital or other general corporate purposes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Pursuant to the terms of the Purchase Agreements, on September 26, 2016, OncoCyte filed a resale registration statement on Form S-1, referred to as the Resale Registration Statement, with the Securities and Exchange Commission, or SEC, to register for sale under the Securities Act of 1933, as amended, or the Securities Act, the shares of OncoCyte common stock sold in the Offering and the shares of OncoCyte common stock, or Warrant Shares, that may be issued if the Warrants are exercised. The SEC declared the Resale Registration Statement effective on October 20, 2016. OncoCyte has agreed to use commercially reasonable efforts to maintain the effectiveness of the Resale Registration Statement under the Securities Act until the earlier of (i) the date that all shares of its common stock covered by the Resale Registration Statement have been sold or can be sold publicly without restriction or limitation under Rule 144 (including, without limitation, the requirement to be in compliance with Rule 144(c)(1)), or (ii) August 29, 2018.</div></div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">OncoCyte was in compliance with the aforementioned terms of the Purchase Agreement as of the date of this report.</div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Offering Warrants</div></div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Offering Warrants have an exercise price of $3.25 per Warrant Share, and may be exercised for five years from October 17, 2016, the date the Offering Warrants became exercisable. The Warrants may be exercised on a net “cashless exercise” basis, meaning that the value of a portion of Warrant Shares may be used to pay the exercise price (rather than payment in cash), in certain circumstances, including if the Resale Registration Statement is not effective when and as required by the Purchase Agreements. The exercise price and the number of Warrant Shares will be adjusted to account for certain transactions, including stock splits, dividends paid in common stock, combinations or reverse splits of common stock, or reclassifications of common stock.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Under certain provisions of the OncoCyte Offering Warrants, in the event of a Fundamental Transaction, as defined in the Offering Warrants, OncoCyte will use reasonable best efforts for the acquirer, or any successor entity other than OncoCyte, to assume the Offering Warrants. If the acquirer does not assume the OncoCyte Offering Warrant obligations, then the acquirer shall pay the holders of Offering Warrants an amount equal to the aggregate value equal to the Black Scholes Value, as defined in the Offering Warrants. The payment of the Black Scholes Value shall be made in cash or such other consideration as the acquirer paid to the other OncoCyte shareholders in the Fundamental Transaction.</div></div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">OncoCyte is not required to net cash settle the Offering Warrants under any circumstance. </font>OncoCyte considered the guidance in ASC 815-40, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</font>, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. Since solely an acquirer, and not OncoCyte itself, may be required to net cash settle the Offering Warrants in the event of a Fundamental Transaction, the Offering Warrants are classified as equity.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">See Note 10 concerning the exercise of a portion of the Warrants on February 17, 2017 and the issuance of additional stock purchase warrants upon such exercise.</div></div>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<!-- Stockholders' Equity Attributable to Parent -->
<us-gaap:StockholdersEquity contextRef="c20161231" unitRef="U001" decimals="-3"> 9862000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent -->
<us-gaap:StockholdersEquity contextRef="c20151231" unitRef="U001" decimals="-3"> 10417000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Common Stock [Member] -->
<us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 15398000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> -1370000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent -->
<us-gaap:StockholdersEquity contextRef="c20131231" unitRef="U001" decimals="-3"> 3615000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member] -->
<us-gaap:StockholdersEquity contextRef="c20131231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> -10413000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent -->
<us-gaap:StockholdersEquity contextRef="c20141231" unitRef="U001" decimals="-3"> -1074000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member] -->
<us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> -15399000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member] -->
<us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> -24134000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockholdersEquity contextRef="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> -654000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> -350000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Common Stock [Member] -->
<us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 15147000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member] -->
<us-gaap:StockholdersEquity contextRef="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> -35302000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member] -->
<us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> -822000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Common Stock [Member] -->
<us-gaap:StockholdersEquity contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 45818000 </us-gaap:StockholdersEquity>
<!-- Stockholders' Equity Attributable to Parent-Common Stock [Member] -->
<us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 34901000 </us-gaap:StockholdersEquity>
<!-- Subsequent Events [Text Block] -->
<us-gaap:SubsequentEventsTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">10. Subsequent Events</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 17, 2017, certain of OncoCyte investors exercised 625,000 offering Warrants at an exercise price of $3.25 per warrant for total exercise cash proceeds of $2.0 million (the “Warrant exercise”). The offering Warrants had been issued as part of OncoCyte’s financing that was completed on August 29, 2016. See Note 6. In order to induce the investors to complete the Warrant exercise and, in conjunction with the Warrant exercise, OncoCyte issued new warrants to those investors (the “New Warrants”). Certain investors received 200,000 New Warrants with an exercise price of $5.50 per warrant share and the other investor received 212,500 New Warrants with an exercise of $3.25 per warrant share.  The New Warrants are exercisable at any time for five years from February 16 and 17, 2017, respectively. After the Warrant exercise and issuance of the New Warrants to those investors, OncoCyte has an aggregate of 3,033,653 warrants, including the offering Warrants and New Warrants, outstanding at exercise prices ranging from $3.25 and $5.50 per warrant.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">As a result of the issuance of 625,000 shares of OncoCyte common stock from the Warrant exercise, as of February 17, 2017, BioTime owned less than 50% of the OncoCyte outstanding common stock. Under GAAP, loss of control of a subsidiary is deemed to have occurred</font><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt; font-family: 'Times New Roman';">when, among other things, a parent company owns less than a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability to elect a majority of the subsidiary’s Board of Directors. BioTime determined that all of these loss of control factors were present for BioTime as of February 17, 2017.  Accordingly, BioTime has deconsolidated OncoCyte’s financial statements and results of operations from BioTime, effective February 17, 2017, in accordance with ASC, 810-10-40-4(c),</font><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Consolidation</font><font style="font-size: 10pt; font-family: 'Times New Roman';">.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 21, 2017, OncoCyte entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (the “Bank”) pursuant to which OncoCyte obtained a $2 million secured credit facility, (the “First Tranche”). If OncoCyte wishes to borrow the First Tranche, it must do so by April 30, 2017. The credit line may be increased by $3 million (the “Contingent Tranche”) on or after May 1, 2017 if OncoCyte obtains at least $20 million of additional equity capital and launches its initial lung cancer diagnostic test, and is not in default under the Loan Agreement. Payments of interest only on the principal balance will be due monthly from the draw date through October 31, 2017, and, beginning on November 1, 2017, monthly payments of principal and interest will become payable. The outstanding principal balance of the loan will bear interest at a stated floating annual interest rate equal to the greater of (i) three-quarters of one percent (0.75%) above the prime rate or (ii) four and one-quarter percent (4.25%). As of February 21, 2017, the prime rate plus 0.75% was 4.50% per annum.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The principal amount of the First Tranche plus accrued interest will be due and payable to the Bank at maturity on April 1, 2020. The principal amount of all draws under the Contingent Tranche, if any, plus accrued interest will be due and payable to the Bank at maturity on October 1, 2020. At maturity, OncoCyte will also pay the Bank an additional final payment fee of 5.8% of the original principal borrowed. Any amounts borrowed and repaid, may not be reborrowed.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to 3.0% of the outstanding principal balance if prepaid within one year after the February 21, 2017, 2.0% of the outstanding principal balance if prepaid more than one year but less than two years after the February 21, 2017, or 1.0% of the outstanding principal balance if prepaid two years or more after the February 21, 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The outstanding principal amount of the loan, with interest accrued, the final payment fee, and the prepayment fee may become due and payable prior to the applicable maturity date if an “Event of Default” as defined in the Loan Agreement occurs and is not cured within any applicable cure period. An Event of Default includes, among other events, failure to pay interest and principal when due, material adverse changes, which include a material adverse change in OncoCyte’s business, operations, or condition (financial or otherwise), failure to provide the bank with timely financial statements and filings with the Securities and Exchange Commission, as required, legal judgments or pending or threatened legal actions of $50,000 or more, insolvency, and delisting from the NYSE MKT. OncoCyte’s obligations under the Loan Agreement are collateralized by substantially all of its assets other than intellectual property such as patents and trade secrets that OncoCyte owns.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 21, 2017 and in conjunction with the $2 million First Tranche becoming available under the Loan Agreement, OncoCyte issued a common stock purchase warrant to the Bank (the “Bank Warrant”) entitling the Bank to purchase 8,247 shares of OncoCyte common stock at the initial Warrant Price of $4.85 per share through February 21, 2027. The number of shares of common stock issuable upon the exercise of the Bank Warrant will increase on the date of the draw of the First Tranche, and on the date on which OncoCyte meets the conditions of the Contingent Tranche availability, and on the date of the first draw, if any, on the Contingent Tranche. The number of additional shares of common stock issuable upon the exercise of the Bank Warrant will be equal to 2.0% of the First Tranche or Contingent Tranche, as applicable, divided by the Warrant Price determined as provided in the Bank Warrant. The Warrant Price will be determined with reference to the market price of OncoCyte common stock on the date the Contingent Tranche becomes available, or the date on which OncoCyte borrows funds under the First Tranche or Contingent Tranche, as applicable. The Bank may elect to exercise the Bank Warrant on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock.  The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 17, 2017, OncoCyte granted 357,130 stock options to employees with an exercise price of $4.70 per share, determined based on the closing price of the OncoCyte common stock immediately prior to the grant date in accordance with the Plan, subject to standard vesting conditions.</div></div>
</us-gaap:SubsequentEventsTextBlock>
<!-- Selected Balance Sheet Components -->
<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">3. Selected Balance Sheet Components</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Prepaid expenses and other current assets</div><div style="text-align: left; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, prepaid expenses and other current assets were comprised of the following (in thousands):</div><div style="text-align: left; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Outside research</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">366</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Insurance</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">182</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Other prepaid expenses and current asset</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">103</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">22</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Prepaid expenses and other current assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">285</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">388</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Accrued expenses and other current liabilities</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, accrued expenses and other current liabilities were comprised of the following (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accrued bonuses and payroll related expenses</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">549</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">325</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Other accrued expenses</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">248</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">857</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accrued expenses and other current liabilities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">797</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,182</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Intangible assets, net</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In 2011, OncoCyte, through its then parent, BioTime, acquired substantially all of the assets of Cell Targeting, Inc., a company that was engaged in cancer therapy. The assets acquired consist primarily of patents, patent applications, and licenses to use certain patents. OncoCyte amortizes intangible assets over their useful lives estimated to be 10 years at the date of the acquisition.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, intangible assets were comprised of the following (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Intangible assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accumulated amortization</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,431</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,189</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Intangible assets, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">988</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,230</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Amortization expense amounted to approximately $242,000 annually.</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Equipment and furniture, net</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, equipment and furniture were comprised of the following (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Equipment and furniture</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,007</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">750</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accumulated depreciation</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(319</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(174</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 4.13%; background-color: #ffffff;">)</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';"> </div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Equipment and furniture, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">688</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">576</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Depreciation expense amounted to approximately $145,000, $41,000 and $39,000 for the years ended December 31, 2016, 2015 and 2014, respectively. During the year ended December 31, 2016, OncoCyte entered into capital leases for laboratory equipment totaling $626,000.</div></div>
</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
<!-- Accrued interest and penalties -->
<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20161231" unitRef="U001" decimals="-6"> 0 </us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
<!-- Accrued interest and penalties -->
<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20151231" unitRef="U001" decimals="-6"> 0 </us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
<!-- Use of estimates -->
<us-gaap:UseOfEstimates contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Use of estimates</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to going concern assessment of OncoCyte financial statements, the allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.</div></div>
</us-gaap:UseOfEstimates>
<!-- Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount -->
<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c20150101to20151231" unitRef="U001" decimals="-5"> 3900000 </us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
<!-- Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount -->
<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c20160101to20161231" unitRef="U001" decimals="-5"> 5100000 </us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
<!-- Weighted average shares outstanding - basic and diluted (in shares) -->
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20160101to20161231" unitRef="U002" decimals="-3"> 26529000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<!-- Weighted average shares outstanding - basic and diluted (in shares) -->
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20150101to20151231" unitRef="U002" decimals="-3"> 21009000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<!-- Weighted average shares outstanding - basic and diluted (in shares) -->
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20140101to20141231" unitRef="U002" decimals="-3"> 18200000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<!-- Period in which change of ownership for a specified percentage should occur -->
<ocx:PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur contextRef="c20160101to20161231"> P3Y </ocx:PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur>
<!-- Deferred tax Assets, Patents and Fixed Assets -->
<ocx:DeferredTaxAssetsPatentsAndFixedAssets contextRef="c20151231" unitRef="U001" decimals="-3"> 136000 </ocx:DeferredTaxAssetsPatentsAndFixedAssets>
<!-- Deferred tax Assets, Patents and Fixed Assets -->
<ocx:DeferredTaxAssetsPatentsAndFixedAssets contextRef="c20161231" unitRef="U001" decimals="-3"> 179000 </ocx:DeferredTaxAssetsPatentsAndFixedAssets>
<!-- Effective Income Tax Rate Reconciliation, Permanent differences -->
<ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c20150101to20151231" unitRef="U004" decimals="2"> -0.09 </ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
<!-- Effective Income Tax Rate Reconciliation, Permanent differences -->
<ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c20160101to20161231" unitRef="U004" decimals="2"> -0.01 </ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
<!-- Effective Income Tax Rate Reconciliation, Permanent differences -->
<ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c20140101to20141231" unitRef="U004" decimals="2"> -0.02 </ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
<!-- Investors Taxable Gain-BioTime, Inc. [Member] -->
<ocx:InvestorsTaxableGain contextRef="c20150101to20151231_LegalEntityAxis_ParentCompanyMember" unitRef="U001" decimals="-3"> 815000 </ocx:InvestorsTaxableGain>
<!-- Tax Credit Carryforward, Amount, State-Research Tax Credit Carryforward [Member] -->
<ocx:TaxCreditCarryforwardAmountState contextRef="c20161231_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-3"> 905000 </ocx:TaxCreditCarryforwardAmountState>
<!-- Tax Credit Carryforward, Amount, Federal-Research Tax Credit Carryforward [Member] -->
<ocx:TaxCreditCarryforwardAmountFederal contextRef="c20161231_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-3"> 860000 </ocx:TaxCreditCarryforwardAmountFederal>
<!-- Tax Credit Carryforward, Expiration Date, Federal-Research Tax Credit Carryforward [Member]-Maximum [Member] -->
<ocx:TaxCreditCarryforwardExpirationDateFederal contextRef="c20160101to20161231_RangeAxis_MaximumMember_TaxCreditCarryforwardAxis_ResearchMember"> 2036-12-31 </ocx:TaxCreditCarryforwardExpirationDateFederal>
<!-- Tax Credit Carryforward, Expiration Date, Federal-Minimum [Member]-Research Tax Credit Carryforward [Member] -->
<ocx:TaxCreditCarryforwardExpirationDateFederal contextRef="c20160101to20161231_RangeAxis_MinimumMember_TaxCreditCarryforwardAxis_ResearchMember"> 2030-12-31 </ocx:TaxCreditCarryforwardExpirationDateFederal>
<!-- Percentage of change in ownership -->
<ocx:PercentageOfChangeInOwnership contextRef="c20160101to20161231" unitRef="U004" decimals="1"> 0.5 </ocx:PercentageOfChangeInOwnership>
<!-- Period of nontransferable for stock option grants-Employee Stock Option [Member]-Maximum [Member] -->
<ocx:PeriodOfNontransferableForStockOptionGrants contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"> P3M </ocx:PeriodOfNontransferableForStockOptionGrants>
<!-- Share Based Compensation Arrangement By Share Based Payment Award Options Available Grants In Period Gross-Employee Stock Option [Member] -->
<ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 962000 </ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross>
<!-- Share Based Compensation Arrangement By Share Based Payment Award Options Available Grants In Period Gross-Employee Stock Option [Member] -->
<ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3"> 1448000 </ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross>
<!-- Period for exercising vested option-Employee Stock Option [Member] -->
<ocx:PeriodForExercisingVestedOption contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember"> P12M </ocx:PeriodForExercisingVestedOption>
<!-- Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period Maximum Term-Stock Option Plan 2010 [Member] -->
<ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm contextRef="c20160101to20161231_PlanNameAxis_StockOptionPlan2010Member"> P10Y </ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm>
<!-- Percentage of Fair Market Value of Common Stock-Minimum [Member]-Employee Stock Option [Member] -->
<ocx:PercentageOfFairMarketValueOfCommonStock contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U004" decimals="INF"> 1.1 </ocx:PercentageOfFairMarketValueOfCommonStock>
<!-- Share Based Compensation Arrangement By Share Based Payment Award Exercises In Period Maximum Term-Stock Option Plan 2010 [Member] -->
<ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm contextRef="c20160101to20161231_PlanNameAxis_StockOptionPlan2010Member"> P10Y </ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm>
<!-- Related Party Convertible Promissory Note Payable [Text Block] -->
<ocx:RelatedPartyConvertiblePromissoryNotePayableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">5. Related Party Convertible Promissory Note Payable</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In May 2015, OncoCyte entered into Subscription Agreements with BioTime and two other shareholders (see Note 6). In connection with the Subscription Agreements, BioTime purchased 1,500,000 shares of OncoCyte common stock in exchange for the cancellation of $3.3 million of indebtedness owed to BioTime by OncoCyte, and OncoCyte delivered to BioTime a convertible promissory note (the “Note”) for an additional $3.3 million of OncoCyte’s indebtedness to BioTime. The cancellation of the aggregate $6.6 million of indebtedness owed to BioTime was an extinguishment of debt under the provisions of ASC 470-50,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Debt Modification and Extinguishment</font>. Based on a valuation performed by OncoCyte, the issuance date fair value of the Note was $3.3 million and, the fair value of the OncoCyte common stock on the date of the exchange was $3.3 million. Accordingly, no gain or loss resulted from the debt extinguishment.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">BioTime converted the Note into 1,508,095 shares of OncoCyte common stock during November 2015, and upon conversion the note balance and accrued interest was transferred to equity pursuant to ASC 470-20-40-5, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Debt with Conversion and Other Options</font>.</div></div>
</ocx:RelatedPartyConvertiblePromissoryNotePayableTextBlock>
<!-- Term Of Payment-BioTime, Inc. [Member] -->
<ocx:TermOfPayment contextRef="c20160101to20161231_LegalEntityAxis_ParentCompanyMember"> P30D </ocx:TermOfPayment>
<!-- Percentage of Markup Fee Allocated But Not Charged-BioTime, Inc. [Member] -->
<ocx:PercentageOfMarkupFeeAllocatedButNotCharged contextRef="c20160101to20161231_LegalEntityAxis_ParentCompanyMember" unitRef="U004" decimals="INF"> 0.05 </ocx:PercentageOfMarkupFeeAllocatedButNotCharged>
<!-- Allocated Services and Facility Use Fee, Expense-General and Administrative Expense [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3"> 344000 </ocx:AllocatedServicesAndFacilityUseFeeExpense>
<!-- Allocated Services and Facility Use Fee, Expense-General and Administrative Expense [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3"> 595000 </ocx:AllocatedServicesAndFacilityUseFeeExpense>
<!-- Allocated Services and Facility Use Fee, Expense-Research and Development [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20140101to20141231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3"> 552000 </ocx:AllocatedServicesAndFacilityUseFeeExpense>
<!-- Allocated Services and Facility Use Fee, Expense-General and Administrative Expense [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20160101to20161231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3"> 790000 </ocx:AllocatedServicesAndFacilityUseFeeExpense>
<!-- Allocated Services and Facility Use Fee, Expense-Research and Development [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20160101to20161231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3"> 691000 </ocx:AllocatedServicesAndFacilityUseFeeExpense>
<!-- Allocated Services and Facility Use Fee, Expense-Research and Development [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3"> 565000 </ocx:AllocatedServicesAndFacilityUseFeeExpense>
<!-- Allocated Services and Facility Use Fee Payable-Current Liabilities [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeePayable contextRef="c20161231_BalanceSheetLocationAxis_CurrentLiabilitiesMember" unitRef="U001" decimals="-5"> 2900000 </ocx:AllocatedServicesAndFacilityUseFeePayable>
<!-- Allocated Services and Facility Use Fee Payable-Current Liabilities [Member] -->
<ocx:AllocatedServicesAndFacilityUseFeePayable contextRef="c20151231_BalanceSheetLocationAxis_CurrentLiabilitiesMember" unitRef="U001" decimals="0"> 847000 </ocx:AllocatedServicesAndFacilityUseFeePayable>
<!-- Interest on Unpaid Overdue Invoice-BioTime, Inc. [Member] -->
<ocx:InterestOnUnpaidOverdueInvoice contextRef="c20160101to20161231_LegalEntityAxis_ParentCompanyMember" unitRef="U004" decimals="INF"> 0.15 </ocx:InterestOnUnpaidOverdueInvoice>
<!-- Liquidity [Policy Text Block] -->
<ocx:LiquidityPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Liquidity</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">For all periods presented, OncoCyte had generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants to its shareholders, including BioTime, loans from BioTime and other BioTime affiliates, warrant exercises, and a bank loan (see Note 10), and sales of BioTime common shares that OncoCyte held as available-for-sale securities (see Note 2). OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $35.3 million and $24.1 million as December 31, 2016 and 2015, respectively.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte’s research and development efforts are successful to the point where it believes that a commercial product can be launched successfully, then additional capital will be required for developing a sales and marketing team and launching OncoCyte’s first diagnostic test.  Dependent on results of any product commercialization and ongoing sales, if any, additional capital might be required in 2017 or beyond to develop and launch products, for working capital, and for other expenses. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016, we had $10.2 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $2.2 million.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 17, 2017, OncoCyte received cash proceeds of $2.0 million when certain investors exercised 625,000 warrants to purchase OncoCyte common stock at an exercise price of $3.25 per share. The warrants had been issued as part of a financing that was completed on August 29, 2016, through which OncoCyte sold an aggregate of 3,246,153 immediately separable “units”, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (see Note 10).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On February 21, 2017, OncoCyte entered into a Loan and Security Agreement with Silicon Valley Bank for a working capital loan of $2 million, collateralized by substantially all of OncoCyte’s assets other than intellectual property such as patents and trade secrets that OncoCyte owns (see Note 10).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">Based on cash and cash equivalents currently on hand, including the warrant exercises and working capital loan under the Loan Agreement discussed above and in Note 10, OncoCyte believes it has sufficient cash, cash equivalents, available for sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein (see Note 2).</div></div>
</ocx:LiquidityPolicyTextBlock>
<!-- Common Stock Votes Per Share -->
<ocx:CommonStockVotesPerShare contextRef="c20161231" unitRef="U007" decimals="INF"> 1 </ocx:CommonStockVotesPerShare>
<!-- Number of Common Stock Shares Available in Separable Units-BioTime, Inc. [Member] -->
<ocx:NumberOfCommonStockSharesAvailableInSeparableUnits contextRef="c20160829_LegalEntityAxis_ParentCompanyMember" unitRef="U002" decimals="INF"> 1 </ocx:NumberOfCommonStockSharesAvailableInSeparableUnits>
<!-- Number of Common Stock Shares Available in Separable Units -->
<ocx:NumberOfCommonStockSharesAvailableInSeparableUnits contextRef="c20160829" unitRef="U002" decimals="INF"> 1 </ocx:NumberOfCommonStockSharesAvailableInSeparableUnits>
<!-- Separable Units, Exercise Price -->
<ocx:SeparableUnitsExercisePrice contextRef="c20160829" unitRef="U003" decimals="INF"> 3.25 </ocx:SeparableUnitsExercisePrice>
<!-- Issuance of Separable Units -->
<ocx:IssuanceOfSeparableUnits contextRef="c20160829" unitRef="U002" decimals="INF"> 3246153 </ocx:IssuanceOfSeparableUnits>
<!-- Number of shareholders-Stock Purchase Subscription Agreement, First [Member]-Investors [Member] -->
<ocx:NumberOfShareholders contextRef="c20150502to20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U006" decimals="INF"> 2 </ocx:NumberOfShareholders>
<!-- Number of shareholders-Stock Purchase Subscription Agreement, First [Member]-Common Stock [Member]-Investors [Member] -->
<ocx:NumberOfShareholders contextRef="c20150502to20150531_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U006" decimals="INF"> 2 </ocx:NumberOfShareholders>
<!-- Common Stock Dividend, Paid-in-kind-BioTime, Inc. [Member]-Common Stock [Member]-Stock Purchase Subscription Agreement, First [Member] -->
<ocx:CommonStockDividendPaidInKind contextRef="c20150101to20151231_LegalEntityAxis_ParentCompanyMember_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_StockPurchaseSubscriptionAgreementFirstMember" unitRef="U002" decimals="INF"> 30985 </ocx:CommonStockDividendPaidInKind>
<!-- Reverse Stock Split [Policy Text Block] -->
<ocx:ReverseStockSplitPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Reverse stock split</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.</div></div>
</ocx:ReverseStockSplitPolicyTextBlock>
<!-- Going concern assessment [Policy Text Block] -->
<ocx:GoingConcernAssessmentPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Going concern assessment</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">With the implementation of FASB’s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte will assess going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div></div>
</ocx:GoingConcernAssessmentPolicyTextBlock>
<!-- Accounting for warrants [Policy Text Block] -->
<ocx:AccountingForWarrantsPolicyTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Accounting for warrants</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</font><font style="font-size: 10pt; font-family: 'Times New Roman';">, then in accordance with ASC 815-40,</font><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</font><font style="font-size: 10pt; font-family: 'Times New Roman';">.  Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares.  If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature.  If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP.  After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity.  Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations.  Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.</font></div></div>
</ocx:AccountingForWarrantsPolicyTextBlock>
<!-- Common Stock, Shares Held as Available for Sale Securities-BioTime, Inc. [Member] -->
<ocx:CommonStockSharesHeldAsAvailableForSaleSecurities contextRef="c20161231_LegalEntityAxis_ParentCompanyMember" unitRef="U002" decimals="INF"> 619706 </ocx:CommonStockSharesHeldAsAvailableForSaleSecurities>
<!-- Restructuring And Related Cost Expected Severance Obligations for Termination due to Change in Control -->
<ocx:RestructuringAndRelatedCostExpectedSeveranceObligationsForTerminationDueToChangeInControl contextRef="c20161231" unitRef="U001" decimals="-3"> 624000 </ocx:RestructuringAndRelatedCostExpectedSeveranceObligationsForTerminationDueToChangeInControl>
<!-- Percentage of Restocking Fee Paid on Original Cost of Equipment-Master Lease Line Agreement [Member] -->
<ocx:PercentageOfRestockingFeePaidOnOriginalCostOfEquipment contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U004" decimals="INF"> 0.075 </ocx:PercentageOfRestockingFeePaidOnOriginalCostOfEquipment>
<!-- Capital Lease Payment Term-Master Lease Line Agreement [Member] -->
<ocx:CapitalLeasePaymentTerm contextRef="c20160101to20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember"> P36M </ocx:CapitalLeasePaymentTerm>
<!-- Percentage of Fair Value on Original Cost to Purchase an Equipment-Minimum [Member]-Master Lease Line Agreement [Member] -->
<ocx:PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MinimumMember" unitRef="U004" decimals="INF"> 0.125 </ocx:PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment>
<!-- Capital Lease Agreement Imputed Annual Interest Rate-Master Lease Line Agreement [Member] -->
<ocx:CapitalLeaseAgreementImputedAnnualInterestRate contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U004" decimals="INF"> 0.1 </ocx:CapitalLeaseAgreementImputedAnnualInterestRate>
<!-- Amount Available under Capital Lease Agreement-Master Lease Line Agreement [Member] -->
<ocx:AmountAvailableUnderCapitalLeaseAgreement contextRef="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3"> 249000 </ocx:AmountAvailableUnderCapitalLeaseAgreement>
<!-- Restructuring And Related Cost Expected Severance Obligations for Termination without Cause -->
<ocx:RestructuringAndRelatedCostExpectedSeveranceObligationsForTerminationWithoutCause contextRef="c20161231" unitRef="U001" decimals="-3"> 420000 </ocx:RestructuringAndRelatedCostExpectedSeveranceObligationsForTerminationWithoutCause>
<!-- Minimum Fixed Payment Due Shared Facility Agreement -->
<ocx:MinimumFixedPaymentDueSharedFacilityAgreement contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 15000 </ocx:MinimumFixedPaymentDueSharedFacilityAgreement>
<!-- Proceeds From Issuance Of Common Stock Shares And Warrants Net Of Discounts And Financing Costs-Common Stock [Member] -->
<ocx:ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 3246000 </ocx:ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts>
<!-- Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs -->
<ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 9777000 </ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
<!-- Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs-Common Stock [Member] -->
<ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 9777000 </ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
<!-- Common Stock Dividends Shares Received-Common Stock [Member] -->
<ocx:CommonStockDividendsSharesReceived contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 31000 </ocx:CommonStockDividendsSharesReceived>
<!-- Common Stock Shares Issued for Cash-Common Stock [Member] -->
<ocx:CommonStockSharesIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 2711000 </ocx:CommonStockSharesIssuedForCash>
<!-- Common Stock Issued for Cash-Accumulated Deficit [Member] -->
<ocx:CommonStockIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedForCash>
<!-- Common Stock Issued for Cash-Common Stock [Member] -->
<ocx:CommonStockIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 8349000 </ocx:CommonStockIssuedForCash>
<!-- Common Stock Issued for Cash-Accumulated Other Comprehensive Loss [Member] -->
<ocx:CommonStockIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedForCash>
<!-- Common Stock Issued for Cash -->
<ocx:CommonStockIssuedForCash contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 8349000 </ocx:CommonStockIssuedForCash>
<!-- Common Stock Shares Issued Conversion Of Convertible Note Payable And Accrued Interest-Common Stock [Member] -->
<ocx:CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 1508000 </ocx:CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
<!-- Common Stock Issued to Investors for Cash-Accumulated Deficit [Member] -->
<ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedToInvestorsForCash>
<!-- Common Stock Issued to Investors for Cash-Common Stock [Member] -->
<ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 3300000 </ocx:CommonStockIssuedToInvestorsForCash>
<!-- Common Stock Issued to Investors for Cash-Accumulated Other Comprehensive Loss [Member] -->
<ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedToInvestorsForCash>
<!-- Common Stock Issued to Investors for Cash -->
<ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 3300000 </ocx:CommonStockIssuedToInvestorsForCash>
<!-- Common Stock Shares Issued to Investors for Cash-Common Stock [Member] -->
<ocx:CommonStockSharesIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3"> 1500000 </ocx:CommonStockSharesIssuedToInvestorsForCash>
<!-- Transfer of realized loss into equity from sale of shares -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Transfer of realized loss into equity from sale of shares-Accumulated Other Comprehensive Loss [Member] -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 397000 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Transfer of realized loss into equity from sale of shares-Common Stock [Member] -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> -569000 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Transfer of realized loss into equity from sale of shares -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 0 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Transfer of realized loss into equity from sale of shares-Common Stock [Member] -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> -397000 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Transfer of realized loss into equity from sale of shares-Accumulated Other Comprehensive Loss [Member] -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 569000 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Transfer of realized loss into equity from sale of shares-Accumulated Deficit [Member] -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Transfer of realized loss into equity from sale of shares-Accumulated Deficit [Member] -->
<ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20140101to20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
<!-- Percentage of Additional Shares of Common Stock Issuable upon exercise-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<ocx:PercentageOfAdditionalSharesOfCommonStockIssuableUponExercise contextRef="c20170221to20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2"> 0.02 </ocx:PercentageOfAdditionalSharesOfCommonStockIssuableUponExercise>
<!-- Issuance Of Common Stock And Warrants-BioTime, Inc. [Member]-Subsequent Event [Member] -->
<ocx:IssuanceOfCommonStockAndWarrants contextRef="c20170217to20170217_LegalEntityAxis_ParentCompanyMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="INF"> 625000 </ocx:IssuanceOfCommonStockAndWarrants>
<!-- Issuance Of Common Stock And Warrants-Subsequent Event [Member] -->
<ocx:IssuanceOfCommonStockAndWarrants contextRef="c20170217to20170217_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="INF"> 625000 </ocx:IssuanceOfCommonStockAndWarrants>
<!-- Class of Warrant or Right, Exercised Period -->
<ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20160101to20161231"> P5Y </ocx:ClassOfWarrantOrRightExercisedPeriod>
<!-- Class of Warrant or Right, Exercised Period-Subsequent Event [Member] -->
<ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170217to20170217_SubsequentEventTypeAxis_SubsequentEventMember"> P5Y </ocx:ClassOfWarrantOrRightExercisedPeriod>
<!-- Additional Final Payment Fee Percentage-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<ocx:AdditionalFinalPaymentFeePercentage contextRef="c20170221to20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="3"> 0.058 </ocx:AdditionalFinalPaymentFeePercentage>
<!-- Additional Equity Capital-Silicon Valley Bank [Member]-Subsequent Event [Member] -->
<ocx:AdditionalEquityCapital contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-6"> 20000000 </ocx:AdditionalEquityCapital>
<!-- Prepayment Fee if Prepaid More than One Year but Less than Two Years-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<ocx:PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears contextRef="c20170221to20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2"> 0.02 </ocx:PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears>
<!-- Prepayment Fee if Prepaid Two Years or More-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<ocx:PrepaymentFeeIfPrepaidTwoYearsOrMore contextRef="c20170221to20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2"> 0.01 </ocx:PrepaymentFeeIfPrepaidTwoYearsOrMore>
<!-- Prepayment Fee if Prepaid within One Year-Subsequent Event [Member]-Silicon Valley Bank [Member] -->
<ocx:PrepaymentFeeIfPrepaidWithinOneYear contextRef="c20170221to20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2"> 0.03 </ocx:PrepaymentFeeIfPrepaidWithinOneYear>
<!-- Penalty Amount in Event of Default-Minimum [Member]-Silicon Valley Bank [Member]-Subsequent Event [Member] -->
<ocx:PenaltyAmountInEventOfDefault contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_RangeAxis_MinimumMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0"> 50000 </ocx:PenaltyAmountInEventOfDefault>
<!-- Line of Credit Facility Amount by Which Credit Line Can be Increased-Silicon Valley Bank [Member]-Subsequent Event [Member] -->
<ocx:LineOfCreditFacilityAmountByWhichCreditLineCanBeIncreased contextRef="c20170221_LineOfCreditFacilityAxis_SiliconValleyBankMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-6"> 3000000 </ocx:LineOfCreditFacilityAmountByWhichCreditLineCanBeIncreased>
<!-- Security deposit received -->
<ocx:SecurityDepositReceived contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </ocx:SecurityDepositReceived>
<!-- Security deposit received -->
<ocx:SecurityDepositReceived contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> -75000 </ocx:SecurityDepositReceived>
<!-- Security deposit received -->
<ocx:SecurityDepositReceived contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 0 </ocx:SecurityDepositReceived>
<!-- Proceeds From Issuance Of Common Shares And Warrants -->
<ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 10550000 </ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants>
<!-- Proceeds From Issuance Of Common Shares And Warrants -->
<ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants>
<!-- Proceeds From Issuance Of Common Shares And Warrants -->
<ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 0 </ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants>
<!-- Common stock issued conversion of convertible note payable and accrued interest-Common Stock [Member] -->
<ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3"> 3318000 </ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
<!-- Common stock issued conversion of convertible note payable and accrued interest-Accumulated Other Comprehensive Loss [Member] -->
<ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
<!-- Common stock issued conversion of convertible note payable and accrued interest -->
<ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 3318000 </ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
<!-- Common stock issued conversion of convertible note payable and accrued interest-Accumulated Deficit [Member] -->
<ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
<!-- Common stock issued conversion of convertible note payable and accrued interest -->
<ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
<!-- Common stock issued conversion of convertible note payable and accrued interest -->
<ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
<!-- Contingently issuable warrant expense to investors -->
<ocx:ContingentlyIssuableWarrantExpenseToInvestors contextRef="c20150101to20151231" unitRef="U001" decimals="-3"> 65000 </ocx:ContingentlyIssuableWarrantExpenseToInvestors>
<!-- Contingently issuable warrant expense to investors -->
<ocx:ContingentlyIssuableWarrantExpenseToInvestors contextRef="c20160101to20161231" unitRef="U001" decimals="-3"> 0 </ocx:ContingentlyIssuableWarrantExpenseToInvestors>
<!-- Contingently issuable warrant expense to investors -->
<ocx:ContingentlyIssuableWarrantExpenseToInvestors contextRef="c20140101to20141231" unitRef="U001" decimals="-3"> 0 </ocx:ContingentlyIssuableWarrantExpenseToInvestors>
<!-- Prepaid Research and Development, and Consulting Expense, Current -->
<ocx:PrepaidResearchAndDevelopmentAndConsultingExpenseCurrent contextRef="c20151231" unitRef="U001" decimals="-3"> 366000 </ocx:PrepaidResearchAndDevelopmentAndConsultingExpenseCurrent>
<!-- Prepaid Research and Development, and Consulting Expense, Current -->
<ocx:PrepaidResearchAndDevelopmentAndConsultingExpenseCurrent contextRef="c20161231" unitRef="U001" decimals="-3"> 0 </ocx:PrepaidResearchAndDevelopmentAndConsultingExpenseCurrent>
<!-- Schedule of Prepaid Expenses and Other Current Assets [Table Text Block] -->
<ocx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, prepaid expenses and other current assets were comprised of the following (in thousands):</div><div style="text-align: left; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Outside research</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">366</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Insurance</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">182</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Other prepaid expenses and current asset</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">103</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">22</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Prepaid expenses and other current assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">285</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">388</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div>
</ocx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
<!-- Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block] -->
<ocx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c20160101to20161231">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2016 and 2015, accrued expenses and other current liabilities were comprised of the following (in thousands):</div><div style="text-align: justify; text-indent: 36pt;"><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accrued bonuses and payroll related expenses</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">549</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">325</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 74%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Other accrued expenses</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">248</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 6%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">857</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 4.13%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 74%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Accrued expenses and other current liabilities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">797</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 6%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,182</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 4.13%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div>
</ocx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> No stock options were granted in 2014. </link:footnote>
<link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator"/>
<link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc"/>
<link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator"/>
<link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-1" xlink:type="arc"/>
<link:loc xlink:href="#Item-3" xlink:label="Item-3_lbl" xlink:type="locator"/>
<link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-3_lbl" xlink:to="Footnote-Item-1" xlink:type="arc"/>
<link:loc xlink:href="#Item-4" xlink:label="Item-4_lbl" xlink:type="locator"/>
<link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-4_lbl" xlink:to="Footnote-Item-1" xlink:type="arc"/>
</link:footnoteLink>
</xbrl>

7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/10/24  Oncocyte Corp.                    S-3                    5:378K                                   M2 Compliance LLC/FA
 4/16/24  Oncocyte Corp.                    10-K       12/31/23   87:30M                                    M2 Compliance LLC/FA
 4/12/23  Oncocyte Corp.                    10-K       12/31/22   94:11M                                    M2 Compliance LLC/FA
 5/02/22  Oncocyte Corp.                    10-K/A     12/31/21   12:649K                                   M2 Compliance LLC/FA
 3/11/22  Oncocyte Corp.                    10-K       12/31/21   90:10M                                    M2 Compliance LLC/FA
 4/30/21  OncoCyte Corp.                    10-K/A     12/31/20    2:488K                                   M2 Compliance LLC/FA
 3/19/21  OncoCyte Corp.                    10-K       12/31/20   93:7.4M                                   M2 Compliance LLC/FA
↑Top
Filing Submission 0001140361-17-009369   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 16, 1:31:36.2am ET